https://trial.medpath.com/news/ancient-chinese-root-polygonum-multiflorum-shows-multi-target-potential-against-androgenetic-alopecia 2026-06-07T11:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/vitamin-d-supplementation-in-pregnancy-does-not-prevent-preterm-birth-meta-analysis-finds 2026-06-07T11:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/vibrio-vulnificus-expands-northward-along-u-s-atlantic-coast-as-climate-change-fuels-spread-researchers-race-to-build-early-warning-system 2026-06-07T11:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/edwards-lifesciences-draws-strong-institutional-interest-as-analysts-maintain-bullish-outlook 2026-06-07T11:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/process-analytical-technology-reshapes-pharma-manufacturing-from-end-product-testing-to-real-time-quality-assurance 2026-06-07T10:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/how-ai-powered-drug-discovery-is-accelerating-breakthroughs-across-oncology-cardiology-and-metabolic-disease 2026-06-07T07:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/ai-medical-reference-tools-face-accuracy-scrutiny-as-physician-adoption-surges 2026-06-07T07:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/health-security-intelligence-operations-center-launches-at-georgetown-university-to-track-world-cup-disease-risks 2026-06-07T06:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/novonesis-and-turtletree-partner-to-scale-precision-fermented-lactoferrin-for-global-nutrition-markets 2026-06-07T05:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/xrhealth-acquires-swing-therapeutics-to-expand-digital-therapeutics-portfolio 2026-06-07T05:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/the-gut-brain-axis-in-ibd-anxiety-depression-comorbidity-a-network-of-four-interconnected-inflammatory-pathways 2026-06-07T04:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/alcohol-may-trick-the-brain-into-craving-junk-food-via-the-hormone-fgf21-study-suggests 2026-06-07T04:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/abcellera-appoints-dr-lynn-seely-former-myovant-ceo-and-xtandi-development-lead-to-board-of-directors 2026-06-07T03:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/as-adolescent-overdoses-rise-states-move-to-put-naloxone-in-schools 2026-06-07T03:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/leo-cancer-care-raises-65m-series-d-following-world-first-upright-proton-therapy-treatment-at-stanford-medicine 2026-06-07T03:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/allergy-action-ireland-urges-national-rollout-of-oral-immunotherapy-following-success-at-cork-university-hospital 2026-06-07T02:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/saliva-based-surrogate-marker-predicts-malignant-transformation-in-oral-potentially-malignant-disorders 2026-06-07T02:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/mayim-bialik-details-severe-adverse-reaction-to-glp-1-medication-prescribed-for-autoimmune-inflammation 2026-06-07T02:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/insulet-vs-dexcom-which-diabetes-technology-stock-offers-better-value-in-2026 2026-06-07T00:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/phytic-acid-in-plant-foods-activates-hdac3-to-strengthen-gut-barrier-preclinical-study-finds 2026-06-07T00:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/study-challenges-assumption-that-summer-sun-restores-vitamin-d-levels-in-high-risk-groups 2026-06-06T23:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-pipeline-driven-resilience-darzalex-carvykti-and-tremfya-fuel-10-revenue-growth-amid-stelara-patent-cliff 2026-06-06T23:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/distinct-epigenetic-signatures-reveal-how-aging-and-type-2-diabetes-differently-reshape-pancreatic-islets 2026-06-06T22:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/serena-williams-comeback-ignites-debate-on-glp-1s-and-performance-enhancement-in-elite-sports 2026-06-06T22:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-torch-surveillance-reveals-persistent-congenital-infection-risks-in-north-india-despite-vaccination-gains 2026-06-06T22:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/royalty-pharma-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference 2026-06-06T22:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/advocacy-groups-push-back-against-virginia-s-proposed-900-increase-in-public-cannabis-use-fines 2026-06-06T22:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/eight-common-food-preservatives-linked-to-hypertension-and-cardiovascular-risk-in-large-french-cohort-study 2026-06-06T21:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/single-fraction-sbrt-shows-promise-in-localized-prostate-cancer-meeting-primary-endpoint-in-phase-1-2-trial 2026-06-06T21:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/climb-bio-s-clym116-demonstrates-clean-phase-1-safety-profile-advancing-toward-igan-patient-studies-in-2026 2026-06-06T20:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-mammography-expands-beyond-cancer-detection-to-predict-cardiovascular-risk 2026-06-06T19:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/pre-travel-health-planning-essential-as-summer-travel-surges-experts-warn 2026-06-06T19:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/biomarkers-and-precision-oncology-forum-2026-to-feature-agnostic-molecular-tumor-board-and-leading-experts-in-singapore 2026-06-06T19:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-houston-launches-uh-health-a-cross-disciplinary-academic-health-enterprise-to-address-texas-healthcare-challenges 2026-06-06T19:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/obinutuzumab-demonstrates-86-overall-remission-in-refractory-membranous-nephropathy-first-single-arm-meta-analysis 2026-06-06T19:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/traditional-medicare-vs-medicare-advantage-how-seniors-can-choose-the-plan-that-still-works-when-health-needs-change 2026-06-06T19:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/msk-kids-expands-pediatric-cellular-therapy-program-under-leadership-of-dr-kevin-curran 2026-06-06T18:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/alliance-clinical-network-and-atlas-clinical-research-merge-to-form-national-clinical-trial-platform 2026-06-06T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/eclinical-solutions-market-to-reach-40-7-billion-by-2034-driven-by-ai-decentralized-trials-and-cloud-adoption 2026-06-06T18:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/newer-glp-1s-pushback-on-research-cuts-and-a-protest-at-ada-2026 2026-06-06T17:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-trial-access-significantly-lower-for-people-living-with-hiv-study-finds 2026-06-06T17:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-protein-degradation-the-next-frontier-in-drugging-the-undruggable 2026-06-06T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-blood-test-accurately-classifies-multiple-neurodegenerative-diseases-and-detects-co-existing-conditions 2026-06-06T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/pcn-seals-572-medicine-outlets-in-plateau-state-over-widespread-regulatory-violations 2026-06-06T17:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/senseonics-reports-record-q2-2026-revenue-raises-full-year-guidance-on-surging-eversense-cgm-demand 2026-06-06T17:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/global-rise-in-delayed-childbearing-and-infertility-drives-demand-for-cross-border-fertility-care 2026-06-06T17:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-multiple-myeloma-patient-seeks-car-t-cell-therapy-in-china-amid-domestic-access-gaps 2026-06-06T16:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/ractigen-s-sarna-candidate-lico-saucp1-demonstrates-high-quality-weight-loss-without-muscle-wasting-or-rebound-in-preclinical-obesity-models 2026-06-06T16:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/reid-hoffman-leaves-microsoft-board-to-pursue-founder-mode-at-ai-drug-discovery-startup-manus 2026-06-06T15:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/cost-effectiveness-of-genome-guided-statin-treatment-for-hypercholesterolemia 2026-06-06T14:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/pcsk9-inhibitors-linked-to-improved-survival-in-cancer-patients-receiving-immunotherapy-study-finds 2026-06-06T14:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/us-measles-cases-surpass-2000-for-second-consecutive-year-elimination-status-at-risk 2026-06-06T13:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/redlands-community-hospital-opens-jack-and-laura-dangermond-center-for-radiation-therapy-expanding-local-cancer-care-access 2026-06-06T12:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/chronic-teen-cannabis-use-linked-to-reduced-brain-iron-and-dopamine-dysfunction-raising-addiction-risk 2026-06-06T11:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-pipeline-momentum-key-regulatory-wins-clinical-updates-and-setbacks-reshape-outlook 2026-06-06T11:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/from-patient-to-pioneer-how-fshd-researchers-are-redefining-a-rare-disease-through-epigenetics-and-crispr 2026-06-06T10:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/kgh-becomes-first-government-hospital-in-andhra-pradesh-to-offer-free-immunotherapy-for-stage-iv-lung-cancer-patients 2026-06-06T10:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-academy-graduates-156-students-at-10th-convocation-launches-new-ai-and-dmpk-programs 2026-06-06T10:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/aspire-cohort-launches-as-first-large-scale-longitudinal-cancer-study-focused-on-asian-americans 2026-06-06T09:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/liver-failure-warning-signs-recognizing-end-stage-disease-and-hepatic-encephalopathy 2026-06-06T09:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/grunenthal-completes-phase-i-trial-for-first-in-class-nop-agonist-plans-phase-ii-in-acute-pain 2026-06-06T09:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/spark-colorado-announces-cohort-9-nine-projects-advancing-cell-therapies-ai-tools-and-novel-biologics 2026-06-06T09:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/john-m-kane-receives-2026-sirs-lifetime-achievement-award-for-transformative-schizophrenia-research 2026-06-06T08:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/rivus-pharmaceuticals-unveils-preclinical-data-for-muscle-preserving-oral-glp-1-agonist-rv-8451-at-ada-2026 2026-06-06T08:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/rogue-dna-repair-gene-exo1-creates-brca-like-vulnerability-in-multiple-cancers 2026-06-06T07:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/operational-redesign-not-just-more-staff-holds-the-key-to-improving-gp-access 2026-06-06T07:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/ipc-to-lead-national-materiovigilance-capacity-building-drive-at-nimhans-bengaluru 2026-06-06T05:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/fn1-macrophages-drive-aggressive-sarcomatoid-differentiation-and-immunotherapy-resistance-in-renal-cell-carcinoma 2026-06-06T03:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-cellular-reprogramming-attracts-major-investment-as-biotech-firms-target-us-610-billion-longevity-market 2026-06-06T03:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/new-mexico-faces-escalating-overdose-crisis-as-fentanyl-potency-surges-and-tranquilizer-adulterated-drugs-spread 2026-06-06T03:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-survivorship-care-a-roadmap-for-life-after-treatment 2026-06-06T01:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/ada-2026-standards-elevate-cardiorenal-risk-reduction-to-co-primary-goal-recommend-earlier-glp-1-and-sglt-2-use 2026-06-06T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/dnlitetm-assay-demonstrates-independent-renal-risk-prediction-in-landmark-credence-trial-analysis 2026-06-06T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1s-and-the-unchanged-moral-narrative-of-thinness-a-cultural-analysis 2026-06-06T00:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/nevada-proposes-six-month-moratorium-on-new-hospice-and-home-health-licenses-amid-fraud-investigation 2026-06-06T00:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-pharma-4-0-market-projected-to-reach-usd-90-71-billion-by-2034-growing-at-19-80-cagr 2026-06-06T00:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/first-precise-base-editing-of-human-embryos-achieved-but-mosaicism-and-safety-concerns-persist 2026-06-06T00:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-prevails-in-talc-ovarian-cancer-lawsuit-as-los-angeles-jury-finds-no-negligence 2026-06-06T00:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/new-laboratory-tool-opens-door-to-better-treatments-for-rare-and-deadly-melanomas 2026-06-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-method-reveals-hidden-self-harm-histories-in-veterans-medical-records-quadrupling-detection-rates 2026-06-05T23:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/icpr-2025-european-psychedelic-research-confronts-negative-trials-ethical-breaches-and-the-challenge-of-inclusivity 2026-06-05T23:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/nih-launches-oriva-office-to-accelerate-nonanimal-human-based-research-methods 2026-06-05T22:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/noveris-health-sciences-re-engages-api-for-psilocybin-drug-development-and-joins-bio 2026-06-05T22:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/ethiopia-confirms-first-marburg-virus-disease-outbreak-19-cases-64-3-fatality-rate-and-a-coordinated-international-response 2026-06-05T21:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/first-proton-therapy-system-arrives-in-nebraska-ending-proton-desert-for-central-u-s-cancer-patients 2026-06-05T21:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-biotech-startups-take-center-stage-at-boston-roadshow-as-us-investors-signal-selective-recovery-in-2026 2026-06-05T21:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/study-challenges-long-held-mechanism-of-hdac-inhibitors-in-cancer-treatment 2026-06-05T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/neuronoff-implants-first-patient-in-dod-funded-trial-of-minimally-invasive-injectrode-for-neurogenic-bladder-in-spinal-cord-injury 2026-06-05T20:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/two-nih-researchers-arrested-for-allegedly-smuggling-monkeypox-virus-samples-into-the-united-states 2026-06-05T20:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-unanimously-sides-with-generic-drugmakers-in-skinny-label-patent-case 2026-06-05T20:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/building-the-plane-while-flying-it-operational-realities-of-cell-and-gene-therapy-program-development 2026-06-05T20:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/stevens-johnson-syndrome-understanding-medication-triggers-timing-and-the-critical-window-for-diagnosis 2026-06-05T20:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-identifies-12-proteins-linking-cholesterol-and-inflammation-in-ischemic-heart-disease-pointing-to-dual-target-therapies 2026-06-05T19:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/new-risk-prediction-tool-identifies-breast-cancer-survivors-most-likely-to-develop-heart-failure-within-10-years 2026-06-05T19:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-argenx-s-vyvgart-label-expansion-to-all-adult-gmg-patients-in-may-2026 2026-06-05T19:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/deadly-multi-state-listeria-outbreak-traced-to-clover-hill-dairy-soft-cheese-one-death-reported 2026-06-05T19:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/generic-drug-industry-transformation-biosimilars-and-complex-generics-drive-new-growth-for-sandoz-teva-and-viatris 2026-06-05T19:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/oxetane-to-azetidine-skeletal-editing-a-single-atom-transmutation-strategy-for-drug-discovery 2026-06-05T18:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/facioscapulohumeral-muscular-dystrophy-market-poised-for-transformative-growth-as-gene-targeted-therapies-advance-toward-regulatory-submissions 2026-06-05T18:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/vivos-inc-receives-fda-ide-approval-to-initiate-first-in-human-study-of-radiogel-r-for-papillary-thyroid-carcinoma 2026-06-05T18:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/ai-detects-early-epilepsy-signs-in-eeg-data-without-visible-seizures 2026-06-05T18:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/target-recalls-up-up-baby-wipes-nationwide-after-fda-testing-detects-burkholderia-contamination 2026-06-05T18:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/creatine-may-supercharge-dendritic-cells-to-boost-cancer-immunotherapy-response-ucla-study-finds 2026-06-05T18:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/rna-based-molecular-test-more-accurately-distinguishes-active-c-difficile-infection-from-colonization 2026-06-05T18:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/community-oncology-at-a-crossroads-how-infrastructure-investment-is-reshaping-cancer-care-delivery 2026-06-05T18:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/favorable-lifestyle-factors-reduce-dementia-risk-across-key-genetic-profiles-japanese-study-finds 2026-06-05T17:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/lipid-nanoparticle-platform-delivers-full-length-antibodies-inside-cells-opening-new-frontier-for-intracellular-targets 2026-06-05T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/tigit-emerges-as-a-breakthrough-second-generation-immune-checkpoint-target-to-overcome-cancer-immunotherapy-resistance 2026-06-05T17:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/vcare-pharmatech-s-next-generation-trk-inhibitor-eratrectinib-wins-nmpa-approval-for-ntrk-fusion-positive-solid-tumors 2026-06-05T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/plants-could-serve-as-miniature-drug-factories-for-astronauts-on-deep-space-missions-uc-san-diego-study-shows 2026-06-05T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-subsidiary-invests-eur7-million-in-gate2brain-to-advance-first-in-class-pediatric-brain-cancer-therapy 2026-06-05T17:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/teva-s-austedo-demonstrates-real-world-quality-of-life-improvements-for-huntington-s-disease-chorea-patients-and-caregivers 2026-06-05T17:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/new-proteomic-map-reveals-how-cancer-metabolism-rewires-t-cell-proteins-opening-immunotherapy-targets 2026-06-05T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiome-emerges-as-the-next-frontier-in-cancer-care-with-landmark-probiotic-trial-set-to-launch 2026-06-05T16:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/dual-ligand-mitochondria-targeted-nanosystem-achieves-85-23-tumor-suppression-in-hepatocellular-carcinoma 2026-06-05T16:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/nickel-0-catalyzed-endo-stereoselective-2-2-cycloaddition-overcomes-norbornadiene-facial-bias 2026-06-05T16:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/potravitug-demonstrates-statistically-significant-viral-clearance-in-phase-ii-bk-polyomavirus-trial-paving-way-for-pivotal-phase-iii 2026-06-05T16:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/flu-drugs-show-promise-against-cognitive-decline-in-hiv-patients-preclinical-study-finds 2026-06-05T16:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-policy-shift-on-ebola-evacuations-raises-alarm-among-infectious-disease-experts 2026-06-05T16:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/longbio-pharma-debuts-on-hong-kong-stock-exchange-at-hk-10-7-billion-valuation-advancing-novel-anti-ige-and-complement-targeting-biologics 2026-06-05T16:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/treosulfan-based-myeloablative-conditioning-enables-donor-specific-tolerance-and-stable-mixed-chimerism-in-allogeneic-transplantation 2026-06-05T15:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/patients-before-monopolies-act-proposed-breakup-of-pbm-owned-pharmacies-could-reshape-drug-pricing-landscape 2026-06-05T15:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/antibody-fragment-eliminates-brain-haemorrhage-risk-in-alzheimer-s-immunotherapy-preclinical-study-shows 2026-06-05T15:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/actg-launches-hiv-cure-study-evaluating-dasatinib-to-target-the-hiv-reservoir 2026-06-05T15:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-pharma-enters-biosimilar-market-with-chime-biologics-partnership-for-dupixent-biosimilar 2026-06-05T14:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/healthcare-ai-is-automating-prior-authorization-backwards-and-why-the-next-leap-must-be-proactive 2026-06-05T12:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/preparative-and-process-chromatography-market-projected-to-reach-29-53-billion-by-2035-driven-by-biologics-manufacturing-boom 2026-06-05T12:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-strengthens-commercial-leadership-with-appointment-of-jim-gute-as-chief-commercial-officer 2026-06-05T12:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-trial-of-ai-designed-universal-coronavirus-vaccine-shows-safety-broad-immune-response 2026-06-05T12:51:04+00:00 hourly 0.9 https://trial.medpath.com/news/optimal-exercise-combination-60-119-minutes-of-strength-training-plus-high-aerobic-activity-linked-to-45-58-lower-mortality-risk 2026-06-05T12:51:03+00:00 hourly 0.9 https://trial.medpath.com/news/nearly-half-of-dementia-cases-are-preventable-lancet-commission-identifies-14-modifiable-risk-factors 2026-06-05T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-leaders-and-nobel-laureates-urge-congress-to-mandate-synthetic-dna-screening-amid-growing-biosecurity-concerns 2026-06-05T11:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/bexobrutideg-shows-high-response-rates-and-manageable-safety-in-btk-degrader-trial-for-relapsed-refractory-cll 2026-06-05T11:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-blocks-colorado-s-first-in-the-nation-prescription-drug-price-cap-on-amgen-s-enbrel 2026-06-05T11:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/chronic-silent-inflammation-the-hidden-driver-of-autoimmune-disease-and-metabolic-decline 2026-06-05T11:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/imaging-cro-services-market-to-reach-3-51-billion-by-2035-driven-by-oncology-trial-complexity-and-ai-integration 2026-06-05T10:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/madras-high-court-rules-chennai-api-maker-s-vildagliptin-exports-to-egypt-infringed-novartis-patent 2026-06-05T10:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/jefferies-analysts-issue-mixed-ratings-on-pharma-giants-novartis-and-sanofi 2026-06-05T10:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/dry-amd-market-poised-for-19-2-cagr-growth-through-2036-as-pipeline-diversifies-beyond-complement-inhibition 2026-06-05T09:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-tenecteplase-trial-challenges-the-4-5-hour-thrombolysis-wall-and-exposes-a-u-s-regulatory-gap 2026-06-05T08:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/kaleida-health-launches-epic-based-integrated-patient-record-system-across-western-new-york 2026-06-05T08:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/the-dad-bod-dilemma-paternal-health-before-conception-may-shape-childhood-obesity-risk-uc-irvine-review-finds 2026-06-05T08:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/ib-neuro-s-srcbv-demonstrates-superior-overall-survival-prediction-in-phase-ii-glioblastoma-trial-at-asco-2026 2026-06-05T08:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/lkcmedicine-class-of-2026-graduates-169-new-doctors-at-convocation-ceremony 2026-06-05T08:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/falling-fentanyl-deaths-drive-historic-24-4-drop-in-u-s-overdose-mortality-but-stimulant-and-xylazine-threats-grow 2026-06-05T07:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-9mw5211-receives-nmpa-and-fda-clearance-for-inflammatory-bowel-disease-clinical-trials 2026-06-05T07:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/azafaros-publishes-phase-2-rainbow-study-data-for-nizubaglustat-in-gm2-gangliosidosis-and-niemann-pick-type-c-disease 2026-06-05T07:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/cms-acute-hospital-care-at-home-program-extended-through-2030-paving-the-way-for-expanded-home-based-inpatient-care 2026-06-05T07:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/roche-secures-ce-mark-for-automated-elecsys-igra-tb-diagnostic-test 2026-06-05T05:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/spdr-s-p-pharmaceuticals-etf-outperforms-biotech-counterparts-with-lower-costs-and-stronger-returns 2026-06-05T05:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/blood-protein-signature-predicts-lung-cancer-risk-more-than-five-years-before-diagnosis 2026-06-05T04:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/agentic-ai-moves-from-experimentation-to-clinical-operations-raising-new-security-and-governance-challenges 2026-06-05T04:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-real-time-release-of-complete-response-letters-faces-legal-challenge-over-transparency-push 2026-06-05T03:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/usaid-dismantling-cripples-ebola-response-in-dr-congo-as-bundibugyo-outbreak-spreads 2026-06-05T03:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/mesenchymal-stem-cells-market-to-reach-usd-9-08-billion-by-2031-growing-at-12-cagr 2026-06-05T03:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-therapies-transform-cancer-into-a-chronic-condition-as-survival-rates-hit-record-highs 2026-06-05T03:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/establishing-ctdna-as-a-validated-primary-surrogate-endpoint-in-solid-tumour-oncology 2026-06-05T01:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/genomic-landscape-of-rare-variants-in-a-chinese-autism-cohort-reveals-novel-risk-genes 2026-06-05T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-surges-on-fda-approval-of-decnupaz-for-rare-blood-cancer-and-european-nod-for-migraine-therapy 2026-06-05T01:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/nsw-government-proposes-landmark-reform-to-medicinal-cannabis-driving-laws-with-three-strike-warning-system 2026-06-05T00:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/common-hypertension-drugs-linked-to-worse-kidney-outcomes-in-type-2-diabetes-patients-despite-modern-therapies 2026-06-05T00:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/ai-in-antibody-discovery-market-to-reach-usd-3-16-billion-by-2034-growing-at-21-57-cagr 2026-06-04T23:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/eic-pavilion-to-showcase-european-biotech-innovators-at-bio-2026-international-convention 2026-06-04T23:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/unodc-launches-international-standards-workshop-to-strengthen-drug-use-disorder-treatment-in-southern-africa 2026-06-04T23:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/clear-protein-emerges-as-popular-lactose-free-alternative-to-traditional-whey-powders 2026-06-04T22:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/hscc-releases-ai-governance-framework-for-healthcare-warning-of-clinical-risks-including-fatal-hallucinations 2026-06-04T22:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/zhengye-biotechnology-receives-nasdaq-non-compliance-notice-over-minimum-bid-price-deficiency 2026-06-04T22:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/acting-fda-commissioner-kyle-diamantas-meets-with-rare-disease-groups-to-repair-strained-relations 2026-06-04T22:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/senate-hearing-exposes-systemic-failures-in-generic-drug-supply-chain-raising-safety-concerns-for-millions-of-americans 2026-06-04T22:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/shapiro-administration-pushes-100-million-innovate-in-pa-2-0-fund-to-accelerate-life-sciences-and-healthcare-innovation 2026-06-04T21:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/pde4b-emerges-as-shared-therapeutic-target-across-tissues-in-systemic-sclerosis 2026-06-04T21:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/senate-hearing-spotlights-unresolved-debate-over-mrna-covid-vaccines-and-cancer-risk 2026-06-04T21:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/study-offers-cautious-reassurance-on-first-trimester-nsaid-use-and-congenital-malformation-risk 2026-06-04T21:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/eu-introduces-mandatory-harmonised-template-for-clinical-trial-recruitment-and-informed-consent-under-ctr 2026-06-04T21:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/remote-work-linked-to-increased-isolation-and-mental-health-decline-in-large-scale-us-study 2026-06-04T21:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-launches-enhanced-dna-to-ind-programme-with-gs-ori-go-vector-technology-to-accelerate-biologics-development 2026-06-04T20:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/scispot-raises-8m-series-a-to-build-ai-native-operating-layer-for-life-sciences-labs 2026-06-04T20:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/haleon-issues-voluntary-nationwide-recall-of-gas-x-extra-strength-softgels-due-to-potential-coolant-contamination 2026-06-04T20:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/cross-reactive-t-cells-discovered-to-target-paramyxovirus-family-offering-broad-protection-against-measles-and-nipah-virus 2026-06-04T20:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-draft-guidance-aims-to-accelerate-cell-and-gene-therapies-by-leveraging-prior-knowledge 2026-06-04T20:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/multiomics-the-systems-approach-reshaping-drug-discovery-and-precision-medicine 2026-06-04T20:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/california-research-bond-for-ucsb-and-uc-system-fails-to-qualify-for-november-ballot-amid-federal-funding-crisis 2026-06-04T20:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-canada-partners-with-nova-scotia-health-innovation-hub-to-accelerate-clinical-research-and-patient-access-to-trials 2026-06-04T19:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/borrelia-mayonii-lyme-disease-detected-in-new-york-for-the-first-time-raising-concerns-about-geographic-spread 2026-06-04T19:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/evosep-launches-evosep-proteomics-ecosystem-to-standardize-lc-ms-based-proteomics-for-drug-development 2026-06-04T18:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/oncovita-unveils-promising-preclinical-data-for-mvdeltac-a-modified-measles-virus-immunotherapy-at-eacr-2026 2026-06-04T18:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/tissue-tmb-outperforms-blood-based-testing-for-predicting-immunotherapy-response-cleveland-clinic-study-confirms 2026-06-04T18:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/celularity-and-fountain-life-launch-investigational-placental-cell-therapy-cenplacel-l-in-florida-under-novel-state-regulatory-framework 2026-06-04T18:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-and-boehringer-halt-2bn-german-investments-as-pharma-industry-protests-drug-spending-curbs 2026-06-04T18:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-issues-drug-safety-update-for-ace-inhibitors-amid-chronic-medicine-shortages 2026-06-04T18:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/jefferies-flags-gsk-s-oncology-pipeline-as-major-value-driver-with-four-near-term-catalysts-in-2026 2026-06-04T18:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/adocia-to-host-virtual-kol-event-reviewing-phase-3-results-of-ultra-rapid-insulin-biochaperone-lispro-in-type-2-diabetes 2026-06-04T18:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/nearly-1-in-5-young-people-turn-to-ai-chatbots-for-mental-health-support-rand-study-finds 2026-06-04T17:11:37+00:00 hourly 0.9 https://trial.medpath.com/news/frontiers-launches-research-topic-on-personalized-approaches-in-gynecologic-oncology-highlighting-precision-medicine-and-rare-tumor-challenges 2026-06-04T17:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/obe-cel-shows-superior-efficacy-over-standard-of-care-in-matched-analysis-for-r-r-b-all 2026-06-04T17:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/google-s-debug-project-seeks-epa-approval-to-release-64-million-wolbachia-infected-mosquitoes-in-california-and-florida 2026-06-04T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/merck-launches-let-s-talk-trials-initiative-to-address-persistent-gaps-in-clinical-trial-representation 2026-06-04T17:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/saliva-biomarkers-can-directly-detect-acute-sleep-deprivation-paving-way-for-roadside-fatigue-testing 2026-06-04T17:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-discover-key-alzheimer-s-tipping-point-in-microglia-that-may-determine-who-gets-dementia 2026-06-04T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-greenlights-first-human-trial-of-mitragynine-for-opioid-use-disorder 2026-06-04T17:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/blood-based-protein-signature-predicts-organ-specific-aging-and-disease-risk-stanford-study-shows 2026-06-04T17:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/cerevasc-secures-85-million-series-c-to-advance-minimally-invasive-eshunt-system-for-normal-pressure-hydrocephalus 2026-06-04T17:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/cell-and-gene-therapy-cdmo-market-projected-to-reach-52-8-billion-by-2034-growing-at-24-5-cagr 2026-06-04T17:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/analysts-maintain-strong-buy-consensus-on-eli-lilly-amid-conflicting-healthcare-sector-sentiments 2026-06-04T17:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/florida-launches-first-in-nation-newborn-whole-genome-sequencing-program-to-detect-nearly-900-rare-diseases 2026-06-04T17:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-rocbrutinib-a-dual-mode-btk-inhibitor-for-drug-resistant-lymphoma 2026-06-04T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/notch2-and-cxcr4-identified-as-key-drivers-of-breast-cancer-dormancy-in-bone-marrow 2026-06-04T16:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/hdbuzz-2025-annual-report-independent-hd-science-journalism-reaches-329000-visitors-amid-accelerating-research 2026-06-04T16:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/melinda-french-gates-commits-additional-215-million-to-women-s-health-targeting-midlife-and-menopause 2026-06-04T16:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/five-years-of-the-global-diabetes-compact-progress-persistent-gaps-and-the-fight-for-universal-insulin-access 2026-06-04T16:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/ladenburg-thalmann-expands-biotechnology-equity-research-team-with-two-senior-analysts 2026-06-04T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/princess-of-wales-visits-cancer-patients-at-the-christie-nhs-foundation-trust-highlighting-holistic-support-services 2026-06-04T16:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/retail-giants-turn-glp-1-prescriptions-into-long-term-customer-relationships-as-employer-coverage-declines 2026-06-04T16:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/bio-techne-and-refeyn-launch-first-integrated-workflow-for-bispecific-antibody-and-biosimilar-characterization 2026-06-04T16:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/cfr-report-warns-u-s-pharmaceutical-supply-chain-faces-rare-earths-level-threat-from-chinese-dependence 2026-06-04T16:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/the-ai-cancer-cure-debate-promise-skepticism-and-the-broader-stakes-of-superhuman-intelligence 2026-06-04T16:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/roswell-park-named-to-newsweek-s-world-s-best-specialized-hospitals-list-for-oncology 2026-06-04T16:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/leonabio-unveils-phase-2-plans-for-brelgometon-ath-1105-in-als-highlighting-biomarker-driven-trial-design-at-summit 2026-06-04T14:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-ranked-no-1-for-patient-engagement-in-rare-diseases-for-second-consecutive-year 2026-06-04T14:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-unveils-pivotal-phase-3-garetosmab-data-in-fop-as-fda-priority-review-underway-alongside-metabolic-and-ophthalmology-pipeline-advances 2026-06-04T14:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/quetiapine-improves-sleep-in-obstructive-sleep-apnea-but-impairs-next-day-driving-performance-small-trial-finds 2026-06-04T14:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/measles-not-ebola-tops-infectious-disease-concerns-for-2026-fifa-world-cup-health-officials-say 2026-06-04T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/attralus-zamubafusp-alfa-receives-fda-orphan-drug-designation-for-al-amyloidosis 2026-06-04T13:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/rossium-subsidiary-seeks-russian-registration-for-second-canakinumab-biosimilar-after-belarus-approval 2026-06-04T13:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/kexing-biopharm-doses-first-subject-in-phase-i-trial-of-bispecific-antibody-gb10-for-neovascular-amd 2026-06-04T12:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/immunotech-b-targets-39-month-timeline-for-eal-resubmission-in-liver-cancer-advances-atl-cell-therapy-commercialization 2026-06-04T12:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-secures-asia-pacific-rights-to-bejescin-the-first-cd20-antibody-approved-for-nmosd 2026-06-04T12:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-saves-stage-4-bowel-cancer-patient-a-decade-long-journey-from-terminal-diagnosis-to-cancer-free 2026-06-04T12:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/how-china-s-legend-biotech-and-llama-nanobodies-changed-the-course-of-multiple-myeloma 2026-06-04T12:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/daltontx-launches-ai-powered-drug-discovery-platform-signs-sygnature-discovery-as-first-client 2026-06-04T11:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/tlr5-receptor-identified-as-key-protective-pathway-in-idiopathic-pulmonary-fibrosis-mouse-studies-show-therapeutic-promise 2026-06-04T11:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/fosnetupitant-outperforms-fosaprepitant-in-long-delayed-cinv-control-for-folfirinox-folfoxiri-regimens 2026-06-04T11:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/uk-regulator-updates-spc-for-senvelgo-oral-solution-in-cats-narrows-indication-and-strengthens-safety-warnings 2026-06-04T11:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/3billion-to-present-on-rare-disease-genomic-diagnostics-and-reanalysis-at-two-european-conferences-in-june-2026 2026-06-04T11:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/ona-therapeutics-raises-86-6-million-series-b-to-advance-first-in-class-adcs-into-clinical-development 2026-06-04T10:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/ocean-warming-patterns-help-predict-malaria-transmission-in-malawi-study-finds 2026-06-04T09:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-submits-accelerated-approval-application-for-povetacicept-in-iga-nephropathy-targets-november-decision 2026-06-04T09:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-abbvie-s-elahere-for-platinum-resistant-ovarian-cancer-marking-first-new-nhs-option-in-over-20-years 2026-06-04T09:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-sector-wide-rally-lifts-exelixis-ptc-therapeutics-and-peers-as-investors-rotate-into-oncology-and-rare-disease-names 2026-06-04T09:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/brain-navi-s-krystolens-single-use-neuro-endoscope-receives-tfda-certification-for-taiwan-market-entry 2026-06-04T09:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/stevanato-group-shareholders-approve-all-resolutions-at-2026-annual-meeting-including-dividend-and-board-appointments 2026-06-04T09:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-s-mhc-i-evasion-trick-backfires-cd4-t-cells-unleash-ferroptosis-against-tumors 2026-06-04T08:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-machine-learning-and-molecular-dynamics-framework-identifies-novel-gsk-3b-inhibitor-candidates-for-alzheimer-s-disease 2026-06-04T08:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/the-cancer-alzheimer-s-paradox-unraveling-the-inverse-relationship-between-two-age-related-diseases 2026-06-04T07:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/mounting-evidence-confirms-no-safe-level-of-alcohol-consumption-cancer-brain-damage-and-mortality-risks-highlighted 2026-06-04T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/seven-critical-challenges-to-curing-brain-tumours-a-call-to-arms-from-cancer-research-uk 2026-06-04T07:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-engineered-hookworms-produce-functional-antitoxin-in-animal-hosts-paving-way-for-living-drug-factories 2026-06-04T07:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-microenvironment-drives-differential-anti-angiogenic-response-in-lung-cancer-subtypes-study-finds 2026-06-04T07:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-family-races-to-fund-personalized-gene-therapy-for-son-s-rare-neurodegenerative-disease 2026-06-04T07:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/china-positions-rare-disease-sector-as-strategic-innovation-frontier-with-34-5-market-growth-projected 2026-06-04T06:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-moves-to-reclassify-top-nih-officials-as-political-appointees-raising-concerns-over-research-independence 2026-06-04T06:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/tau-s-dual-role-essential-for-long-term-memory-formation-yet-disrupted-by-amyloid-beta-in-alzheimer-s 2026-06-04T05:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-updated-cybersecurity-guidance-for-medical-device-premarket-submissions 2026-06-04T05:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/memory-b-cells-reveal-blueprint-for-nasal-vaccines-that-could-stop-respiratory-infections-at-their-entry-point 2026-06-04T04:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/the-adipose-tumor-axis-unraveling-how-fat-tissue-drives-cancer-progression-and-shapes-therapeutic-response 2026-06-04T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/microsoft-and-mayo-clinic-partner-to-build-healthcare-specific-ai-model-for-clinical-reasoning-and-patient-support 2026-06-04T03:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-s-longevity-potential-new-research-links-atp5i-mitochondrial-protein-to-healthy-aging-benefits 2026-06-04T01:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/medicaid-work-requirements-threaten-continuous-coverage-for-cancer-and-hiv-patients-advocates-warn 2026-06-04T01:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/amish-health-paradox-rapid-population-growth-distinct-disease-profiles-and-the-complex-realities-behind-vaccine-narratives 2026-06-04T00:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/adc-therapeutics-lotis-5-trial-meets-pfs-endpoint-but-safety-concerns-cloud-zynlonta-combination-in-dlbcl 2026-06-04T00:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-grants-marketing-authorisation-for-cinnagen-s-teriparatide-biosimilar-zandoriah-a-first-for-iranian-pharma 2026-06-04T00:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/cocrystal-pharma-appoints-antiviral-drug-development-veteran-carol-brosgart-md-to-board-of-directors 2026-06-04T00:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/ironwood-reports-97-linzess-sales-surge-advances-apraglutide-toward-stars-2-trial-initiation 2026-06-04T00:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/the-next-era-of-alzheimer-s-treatment-prevention-trials-combination-therapies-and-biomarker-driven-early-detection-converge 2026-06-04T00:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/silence-therapeutics-reports-positive-phase-ii-zerlasiran-data-and-phase-i-divesiran-results-extends-cash-runway-into-2027 2026-06-04T00:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/montara-therapeutics-secures-1m-michael-j-fox-foundation-grant-to-advance-brain-selective-mtor-therapy-for-parkinson-s-disease 2026-06-04T00:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/bundibugyo-ebola-outbreak-in-drc-declared-public-health-emergency-no-licensed-vaccine-over-1000-cases-in-100-days 2026-06-04T00:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/soccer-heading-linked-to-acute-spikes-in-neural-damage-biomarkers-s100b-and-p-tau217-in-amateur-players 2026-06-04T00:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/trumprx-drug-discount-platform-expands-to-over-750-medications-cms-administrator-oz-announces 2026-06-04T00:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/upc-milan-revokes-remdesivir-patent-for-lack-of-inventive-step-drawing-sharp-distinction-between-reasonable-expectation-and-mere-hope-of-success 2026-06-03T23:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/apoha-emerges-from-stealth-with-36m-to-revolutionize-drug-development-through-molecular-behavior-analysis 2026-06-03T23:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/corrixr-therapeutics-names-seagen-veteran-nancy-whiting-as-board-chair-ahead-of-crispr-oncology-push 2026-06-03T23:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/puma-biotechnology-advances-cancer-pipeline-with-two-phase-ii-trials-for-alisertib 2026-06-03T23:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/biopharmaceutical-innovation-the-patent-imperative-under-siege 2026-06-03T23:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/pds-biotechnology-regains-nasdaq-compliance-after-minimum-bid-price-deficiency 2026-06-03T23:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/rousselot-secures-u-s-patent-for-nextida-gc-a-first-of-its-kind-collagen-peptide-for-post-meal-blood-glucose-support 2026-06-03T23:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-enables-kidney-transplants-in-highly-sensitized-patients-in-first-of-its-kind-trial 2026-06-03T23:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/even-safe-levels-of-air-pollution-linked-to-coronary-artery-disease-especially-in-women 2026-06-03T22:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/multi-omics-and-ai-integration-reshapes-precision-drug-discovery-from-target-identification-to-clinical-translation 2026-06-03T22:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-partners-with-ai-pioneer-inceptive-in-2b-collaboration-to-accelerate-rnai-drug-discovery 2026-06-03T22:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/pune-scientists-develop-dual-gene-silencing-nanocarrier-for-targeted-breast-cancer-therapy 2026-06-03T22:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-launches-section-301-investigation-into-german-drug-pricing-citing-unfair-cost-shifting-to-american-patients 2026-06-03T22:05:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-updates-draft-guidance-on-drug-and-device-manufacturer-communications-with-payors-incorporating-pie-act-provisions 2026-06-03T22:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-and-merck-pursue-divergent-strategies-as-pipeline-pressures-mount 2026-06-03T22:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/zepto-life-technology-receives-fda-breakthrough-device-designation-for-fungiflex-mold-panel-liquid-biopsy-test 2026-06-03T22:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/3d-bioprinting-of-cartilage-tissue-on-the-iss-advances-regenerative-medicine 2026-06-03T21:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/pila-pharma-receives-ema-go-ahead-to-start-obesity-trials-for-trpv1-antagonist-xen-d0501 2026-06-03T21:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-profiling-and-advanced-imaging-guide-personalized-treatment-in-complex-secondary-meningioma-after-childhood-medulloblastoma 2026-06-03T21:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/asbmb-highlights-career-development-and-funding-opportunities-for-biomedical-researchers 2026-06-03T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-to-withdraw-low-dose-zoladex-from-australian-market-raising-concerns-for-breast-cancer-and-endometriosis-patients 2026-06-03T20:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/us-investigation-into-germany-s-drug-pricing-reignites-global-debate-on-pharmaceutical-innovation-costs 2026-06-03T20:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-may-improve-testosterone-levels-and-sperm-quality-in-men-with-obesity-studies-suggest 2026-06-03T20:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/coral-inspired-3d-printed-scaffold-reprograms-immune-cells-to-repair-steroid-induced-bone-death 2026-06-03T19:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-biological-insights-into-progressive-multiple-sclerosis-multi-omics-study-identifies-six-key-proteins-with-therapeutic-potential 2026-06-03T19:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-map-reveals-how-genetic-variation-drives-inflammatory-bowel-disease-opening-new-paths-for-drug-development 2026-06-03T19:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/ai-enabled-antibiotic-discovery-identifies-novel-compounds-against-drug-resistant-gonorrhea 2026-06-03T19:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/schott-pharma-usa-triples-manufacturing-capacity-with-60-million-pennsylvania-expansion 2026-06-03T19:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/ketogenic-therapy-shows-promise-for-anorexia-nervosa-treatment-in-uc-san-diego-clinical-trial 2026-06-03T19:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/house-judiciary-subcommittee-to-examine-drug-patent-protections-amid-tariff-and-pricing-tensions 2026-06-03T19:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/nrf2-s-dual-role-in-ferroptosis-a-context-dependent-switch-for-cancer-therapy 2026-06-03T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/synthetic-human-genome-project-deserves-revival-with-a-new-minimalist-vision 2026-06-03T18:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/more-than-2000-beagles-released-from-wisconsin-research-facility-as-questions-mount-over-federal-oversight 2026-06-03T18:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-spatial-pharmacobiology-platform-reveals-stromal-barriers-to-antibody-delivery-in-human-solid-tumors 2026-06-03T18:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/arb-based-antihypertensive-regimens-show-superior-tolerability-in-large-network-meta-analysis 2026-06-03T18:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/jjp-biologics-reports-positive-phase-1b-data-for-first-in-class-anti-cd89-antagonist-in-rare-autoimmune-disease 2026-06-03T18:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/top-ultra-processed-food-researchers-call-for-sweeping-policy-changes-citing-broad-public-support 2026-06-03T18:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-ai-based-digital-liver-model-into-istand-program-to-predict-drug-induced-liver-injury 2026-06-03T18:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/senior-nih-scientists-charged-with-smuggling-deactivated-mpox-virus-into-u-s-sparking-congressional-investigation 2026-06-03T18:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/analyst-ratings-diverge-on-healthcare-stocks-as-moderna-faces-continued-pressure 2026-06-03T18:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/north-america-dna-sequencing-market-to-reach-27-56-billion-by-2035-driven-by-precision-medicine-and-oncology-applications 2026-06-03T18:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-prices-eur950-million-senior-notes-offering-to-refinance-debt-and-strengthen-financial-flexibility 2026-06-03T18:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/collate-raises-95-million-series-a-to-bring-ai-native-automation-to-regulated-life-sciences-workflows 2026-06-03T18:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/emerging-technologies-aim-to-overcome-immunotherapy-barriers-in-brain-cancers 2026-06-03T18:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-shares-plummet-37-following-phase-3-obefazimod-safety-concerns-in-ulcerative-colitis 2026-06-03T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/neuralight-s-eye-tracking-biomarker-outperforms-mds-updrs-iii-in-detecting-parkinson-s-disease-progression 2026-06-03T17:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-proposes-sweeping-rule-change-to-politicize-federal-science-funding 2026-06-03T16:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/fenebrutinib-shows-efficacy-in-both-relapsing-and-progressive-ms-but-safety-signals-raise-questions 2026-06-03T16:12:54+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference-and-report-q2-2026-financial-results 2026-06-03T16:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-ceo-reports-50-faster-drug-candidate-selection-through-ai-implementation 2026-06-03T16:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-partners-with-ascidian-therapeutics-in-1-9-billion-rna-exon-editing-deal-for-kidney-diseases 2026-06-03T16:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-transplantation-most-cost-effective-curative-option-for-sickle-cell-disease-study-finds 2026-06-03T16:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/cheme-show-2026-highlights-convergence-of-pharmaceutical-and-petrochemical-manufacturing-technologies 2026-06-03T16:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/idefine-partners-with-ut-southwestern-to-develop-first-gene-therapy-for-kleefstra-syndrome 2026-06-03T16:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/vanderbilt-researchers-discover-first-selective-taok1-inhibitor-and-unexpected-pan-taok-activator-opening-new-avenues-for-alzheimer-s-research 2026-06-03T16:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/tearsolutions-receives-fda-orphan-drug-and-fast-track-designations-for-lacripep-in-neurotrophic-keratitis-initiates-phase-2-trial 2026-06-03T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-significant-infection-risks-linked-to-antibody-drug-conjugates-in-cancer-patients 2026-06-03T16:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-vertex-s-biologics-license-application-for-povetacicept-in-iga-nephropathy-setting-november-2026-decision-date 2026-06-03T16:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/cross-linking-mass-spectrometry-reveals-how-influenza-a-virus-rewires-host-cells-at-unprecedented-structural-resolution 2026-06-03T16:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/american-heart-association-launches-first-ever-national-heart-transplant-research-network-to-transform-patient-care 2026-06-03T16:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-and-manchester-secure-major-uk-funding-for-ai-driven-personalised-cancer-vaccines-and-immunotherapy-research 2026-06-03T16:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/hkeybio-launches-comprehensive-autoimmune-disease-model-platform-for-drug-development 2026-06-03T16:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-valneva-lyme-disease-vaccine-shows-73-efficacy-in-phase-3-trial-stony-brook-researchers-report 2026-06-03T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/wvu-medicine-uniontown-expands-robotic-assisted-surgery-with-two-da-vinci-5-systems 2026-06-03T16:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/an-optimistic-outlook-may-protect-the-brain-against-dementia 2026-06-03T16:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/joyce-a-cramer-to-receive-lifetime-accelerator-award-for-transformative-contributions-to-epilepsy-research-and-therapy-development 2026-06-03T16:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/elrig-announces-keynote-lineup-for-drug-discovery-2026-marking-20-years-of-the-flagship-conference 2026-06-03T15:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/kyverna-therapeutics-initiates-first-ever-rolling-bla-for-car-t-therapy-in-stiff-person-syndrome-paving-way-for-autoimmune-neurology-revolution 2026-06-03T15:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-drug-development-poised-to-halve-r-d-timelines-say-sanofi-and-biotech-leaders 2026-06-03T15:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/probio-and-gcp-clinplus-form-strategic-alliance-to-accelerate-cell-and-gene-therapy-trials-in-china 2026-06-03T15:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/mystery-gene-glo1-reveals-novel-anxiety-mechanism-via-methylglyoxal-and-gaba-a-receptors 2026-06-03T15:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-and-male-fertility-what-the-clinical-evidence-actually-shows 2026-06-03T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/research-links-family-weight-comments-to-increased-eating-disorder-risk-in-adolescents 2026-06-03T14:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/sotio-s-lrrc15-targeting-adc-sot106-receives-fda-orphan-drug-designation-for-osteosarcoma-treatment 2026-06-03T14:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-achieves-complete-response-in-stage-four-melanoma-patient 2026-06-03T14:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/musc-introduces-saint-therapy-for-rapid-depression-treatment-achieving-remission-in-days 2026-06-03T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/brain-scans-reveal-two-distinct-biological-subtypes-of-autism 2026-06-03T13:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/mri-biomarkers-revolutionize-clinical-trial-design-for-hereditary-ataxias 2026-06-03T13:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/crc-ceo-chairs-ascp-2026-panel-on-preventable-failure-risk-in-cns-clinical-trials 2026-06-03T13:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/elpasbio-completes-phase-iii-enrollment-for-allojoin-stem-cell-therapy-in-knee-osteoarthritis 2026-06-03T13:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/ucsd-researchers-develop-trace-technology-to-enhance-targeted-drug-delivery-and-reduce-side-effects 2026-06-03T13:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-reports-33-revenue-growth-and-nears-cash-flow-breakeven-as-ameluz-pdt-pipeline-advances 2026-06-03T12:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/weinfuse-and-trial-iq-partner-to-bring-ai-driven-clinical-trials-to-community-infusion-centers 2026-06-03T12:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/axsome-therapeutics-resolves-all-sunosi-patent-litigation-securing-u-s-market-exclusivity-through-2040 2026-06-03T11:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/harmonizing-standards-and-resources-for-the-medical-genome-a-new-framework-for-clinical-genomics 2026-06-03T11:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/pasteurized-akkermansia-muciniphila-supplement-slows-weight-regain-after-diet-induced-loss-phase-2-trial-shows 2026-06-03T11:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/asthma-drug-montelukast-shows-promise-in-overcoming-cancer-immunotherapy-resistance 2026-06-03T11:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/defence-therapeutics-appoints-former-biogen-executive-dr-john-beaver-to-board-of-directors 2026-06-03T11:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/omnix-medical-initiates-phase-ii-trial-of-omn6-for-drug-resistant-acinetobacter-baumannii-infections 2026-06-03T11:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/legend-biotech-reports-promising-safety-data-for-first-in-class-cell-therapy-in-b-cell-lymphoma 2026-06-03T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/gpcr-dimers-and-heteromers-emerging-therapeutic-paradigms-in-neuropsychiatric-disorders 2026-06-03T09:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/platform-trials-emerge-as-solution-to-neurological-drug-development-crisis 2026-06-03T08:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/imaging-endpoints-appoints-srikanth-ayyappan-as-associate-vice-president-of-global-marketing 2026-06-03T08:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/navigating-insurance-coverage-for-behavioral-health-services-what-patients-and-providers-need-to-know 2026-06-03T07:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-study-on-gynecomastia-surgery-in-asian-men-reports-high-patient-satisfaction-with-tailored-surgical-techniques 2026-06-03T07:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/memorial-sloan-kettering-highlights-patient-centered-oncology-with-profiles-of-dr-jessica-ross-and-dr-joshua-drago 2026-06-03T06:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/five-minute-prayer-sessions-significantly-reduce-pain-and-anxiety-in-primary-care-patients-study-finds 2026-06-03T06:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/verisim-life-formalizes-fda-collaboration-to-advance-mechanistic-ai-for-translational-drug-development 2026-06-03T06:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-and-deep-learning-approaches-advance-prediction-of-drug-target-binding-and-drug-drug-interactions 2026-06-03T05:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/lab-grown-human-organoids-poised-to-transform-drug-testing-and-pandemic-preparedness 2026-06-03T05:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/ebola-outbreak-in-drc-fear-misinformation-and-conflict-hamper-containment-as-cases-surpass-340 2026-06-03T03:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-esketamine-preserves-discharge-readiness-and-reduces-propofol-consumption-in-outpatient-bronchoscopy 2026-06-03T02:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/cms-interim-final-rule-on-medicaid-work-reporting-requirements-threatens-coverage-for-cancer-patients-patient-groups-warn 2026-06-03T02:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/uterine-cancer-awareness-early-detection-through-abnormal-bleeding-saves-lives 2026-06-03T01:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/sacred-heart-university-launches-connecticut-s-first-doctor-of-medical-science-program-for-practicing-physician-assistants 2026-06-03T01:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/ilant-health-raises-15m-series-a-to-transform-obesity-care-with-ai-driven-precision-medicine 2026-06-03T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/hopstem-s-hnpc01-earns-fda-rmat-designation-for-chronic-stroke-expands-into-hemorrhagic-stroke-and-tbi 2026-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ultra-widefield-fundus-photography-combined-with-traditional-imaging-identifies-more-advanced-diabetic-retinopathy-cases 2026-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/smart-hydrogel-dressings-redefine-complex-wound-care-from-passive-barriers-to-microenvironment-modulating-platforms 2026-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-immuno-oncology-in-oral-cancer-biomarkers-novel-drug-development-and-nanoparticle-platforms 2026-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/jackson-lab-explores-retinal-imaging-as-non-invasive-biomarker-for-early-alzheimer-s-detection 2026-06-02T23:52:33+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-faces-shareholder-investigation-over-alleged-fiduciary-duty-breaches 2026-06-02T23:52:04+00:00 hourly 0.9 https://trial.medpath.com/news/upstream-bio-to-present-novel-tslp-antagonist-verekitug-at-goldman-sachs-healthcare-conference 2026-06-02T23:51:19+00:00 hourly 0.9 https://trial.medpath.com/news/high-q-technologies-and-creative-biostructure-form-strategic-partnership-to-advance-quantum-epr-spectroscopy-in-drug-discovery 2026-06-02T23:49:11+00:00 hourly 0.9 https://trial.medpath.com/news/trabectedin-plus-radiotherapy-shows-promise-in-retroperitoneal-sarcoma-treatment 2026-06-02T23:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/livzon-s-il-17-inhibitor-lecankitug-nears-second-indication-as-nmpa-accepts-ankylosing-spondylitis-application 2026-06-02T23:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/allen-institute-launches-400m-brain-health-accelerator-to-develop-precision-genetic-therapies-for-neurodegenerative-diseases 2026-06-02T23:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/psychedelic-trials-face-a-methodological-reckoning-as-blinding-failures-and-design-gaps-threaten-regulatory-success 2026-06-02T23:47:56+00:00 hourly 0.9 https://trial.medpath.com/news/a-synuclein-saa-and-mri-imaging-provide-distinct-complementary-information-in-early-parkinson-s-disease-new-study-finds 2026-06-02T23:46:39+00:00 hourly 0.9 https://trial.medpath.com/news/moonlight-therapeutics-launches-first-in-human-trial-of-microneedle-peanut-allergy-treatment 2026-06-02T23:46:33+00:00 hourly 0.9 https://trial.medpath.com/news/first-leishmaniasis-vaccine-using-crispr-gene-editing-clears-fda-hurdle-phase-1-trial-set-to-begin 2026-06-02T23:45:43+00:00 hourly 0.9 https://trial.medpath.com/news/imu-biosciences-raises-53m-to-advance-ai-driven-immune-system-profiling-platform 2026-06-02T23:45:17+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-advances-opaganib-for-bundibugyo-ebola-outbreak-as-cases-surpass-3200 2026-06-02T23:44:52+00:00 hourly 0.9 https://trial.medpath.com/news/urogen-pharma-settles-patent-litigation-with-teva-secures-jelmyto-protection-until-2030 2026-06-02T23:44:46+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-pauses-epilepsy-drug-development-after-phase-2-3-trial-misses-primary-endpoint 2026-06-02T23:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/techbio-company-lucera-launches-with-ai-powered-platform-to-transform-pharmaceutical-r-d-decision-making 2026-06-02T23:40:15+00:00 hourly 0.9 https://trial.medpath.com/news/a-trojan-horse-for-brain-cancer-first-in-human-gene-therapy-trial-shows-promise-in-glioblastoma 2026-06-02T23:39:55+00:00 hourly 0.9 https://trial.medpath.com/news/correctsequence-s-base-editing-therapy-cs-206-shows-15-month-voc-free-success-in-sickle-cell-disease-patient 2026-06-02T23:38:50+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-based-personalized-cancer-treatment-meets-goals-in-late-stage-melanoma-trial 2026-06-02T23:37:16+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-s-mn-166-ibudilast-advances-toward-pivotal-als-data-as-phase-2b-3-combat-als-trial-completes-enrollment 2026-06-02T23:37:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-safety-concerns-force-fulcrum-therapeutics-to-halt-sickle-cell-drug-development 2026-06-02T23:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/passage-bio-and-remix-therapeutics-announce-merger-to-advance-rem-422-an-oral-mrna-degrader-targeting-myb-in-cancer 2026-06-02T23:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-eit-pharma-s-nda-for-lonafarnib-first-oral-therapy-candidate-for-chronic-hepatitis-d 2026-06-02T23:29:36+00:00 hourly 0.9 https://trial.medpath.com/news/vaderis-raises-152-million-to-fund-phase-3-trial-of-akt-inhibitor-engasertib-in-hereditary-haemorrhagic-telangiectasia 2026-06-02T23:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/xenetic-biosciences-reports-dnase-i-enhances-car-t-cell-persistence-and-survival-in-asco-2026-data 2026-06-02T23:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/zoetis-lenivia-gains-uk-approval-as-first-quarterly-anti-ngf-monoclonal-antibody-for-canine-osteoarthritis-pain 2026-06-02T23:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/eccogene-and-astrazeneca-to-present-elecoglipron-clinical-data-at-ada-2026 2026-06-02T23:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-cipepofol-becomes-first-chinese-developed-anesthetic-to-receive-fda-approval 2026-06-02T23:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/intravacc-and-primrose-bio-renew-strategic-partnership-to-advance-conjugate-vaccine-development 2026-06-02T23:24:50+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-reports-positive-phase-3-results-for-remibrutinib-in-multiple-sclerosis 2026-06-02T23:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/cbo-calls-for-urgent-research-as-no-surprises-act-dispute-data-signals-rising-healthcare-costs 2026-06-02T21:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/medical-evacuation-and-repatriation-what-singaporean-travellers-need-to-know 2026-06-02T18:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/training-and-exercise-as-drivers-of-poststroke-neural-repair-mechanisms-and-clinical-translation 2026-06-02T17:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-based-cancer-screening-promise-pitfalls-and-the-question-of-mortality-benefit 2026-06-02T17:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/advancell-raises-315m-series-d-to-advance-targeted-alpha-radiopharmaceuticals-for-cancer 2026-06-02T15:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/rfk-jr-s-hhs-guidelines-on-ssris-spark-fierce-backlash-from-psychiatric-community 2026-06-02T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/pet-imaging-reveals-dopamine-system-injury-not-widespread-inflammation-as-hallmark-of-long-covid-brain-pathology 2026-06-02T15:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/app-based-symptom-monitoring-improves-quality-of-life-in-advanced-cancer-two-randomized-trials 2026-06-02T14:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/national-cancer-survivors-day-2026-five-year-survival-rate-reaches-historic-70-as-research-driven-survivorship-care-gains-momentum 2026-06-02T14:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/genetics-of-parkinson-disease-paradigm-shifts-and-future-prospects 2026-06-02T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-laboratories-vs-intuitive-surgical-divergent-strategies-in-medtech-for-2026 2026-06-02T08:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/2026-medicare-part-a-hospital-deductible-reaches-1736-per-benefit-period-posing-significant-financial-risk-for-beneficiaries 2026-06-02T05:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/therapeutic-activation-of-the-cgas-sting-pathway-emerging-strategies-for-antitumor-immunotherapy-and-antiviral-defense 2026-06-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/antarctic-sea-squirt-compound-shows-selective-melanoma-killing-activity-in-usf-led-expedition 2026-06-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/edap-reports-record-hifu-revenue-in-q4-2025-fda-cleared-next-gen-focal-one-platform-drives-34-growth 2026-06-01T21:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/zai-lab-s-zoci-demonstrates-62-5-intracranial-orr-in-small-cell-lung-cancer-global-bla-submission-planned-for-late-2027 2026-06-01T19:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/could-you-patent-the-sun-the-story-behind-jonas-salk-s-decision-to-forgo-the-polio-vaccine-patent 2026-06-01T16:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/cbih-builds-cannabinoid-psilocybin-research-platform-for-ptsd-targeting-memory-and-emotional-regulation-pathways 2026-06-01T15:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/pathology-driven-biomarkers-emerge-as-critical-tools-for-predicting-immunotherapy-response-in-solid-tumors 2026-06-01T14:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-draft-guidance-aims-to-accelerate-cell-and-gene-therapy-development 2026-06-01T14:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/actinium-pharmaceuticals-appoints-radiotherapy-expert-steffen-heeger-as-chief-medical-officer 2026-06-01T14:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/oak-hill-bio-to-go-public-via-spac-merger-secures-175-million-to-advance-rugonersen-for-angelman-syndrome-through-phase-3 2026-06-01T14:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/digital-twins-of-the-brain-personalized-computational-models-poised-to-transform-neurological-and-psychiatric-treatment 2026-06-01T13:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-s-desi-ms-platform-accelerates-cancer-drug-discovery-with-integrated-synthesis-to-screening-workflow 2026-06-01T13:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/elite-pharmaceuticals-files-anda-for-generic-anticoagulant-targeting-26-billion-market 2026-06-01T13:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-receives-fda-clearance-for-next-generation-il-12-tethered-til-therapy-trial 2026-06-01T13:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/aclarion-s-nociscan-technology-reveals-immune-biomarkers-in-chronic-back-pain-expanding-beyond-surgical-planning 2026-06-01T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/waters-unveils-two-next-generation-mass-spectrometers-at-asms-2026-setting-new-benchmarks-for-multiomics-and-structural-biology 2026-06-01T12:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/rejuvenate-biomed-completes-patient-recruitment-for-phase-2-trial-of-first-in-class-sarcopenia-drug-rjx-01 2026-06-01T12:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/kamada-receives-fda-approval-for-in-house-rabies-virus-neutralization-testing-laboratory 2026-06-01T12:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-nouscom-s-nous-209-for-lynch-syndrome-cancer-prevention 2026-06-01T12:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-advances-three-solid-tumor-programs-with-promising-asco-2026-data 2026-06-01T12:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/biond-biologics-secures-8m-investment-from-gibf-to-advance-novel-immunotherapies-in-china 2026-06-01T12:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/online-resources-on-ai-and-cancer-care-are-scarce-poor-quality-and-omit-critical-safety-risks-study-finds 2026-06-01T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-satri-cel-shows-durable-survival-benefit-in-advanced-gastric-cancer-with-4-5-year-follow-up 2026-06-01T05:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-secures-1-26-billion-licensing-deal-for-hanmi-s-glp-2-drug-sonefpeglutide 2026-06-01T05:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/xtalpi-s-ai-designed-peptide-receives-us-safety-certification-while-pan-tead-inhibitor-advances-to-clinical-trials 2026-06-01T05:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/korean-pharmaceutical-companies-launch-new-low-dose-pitavastatin-combination-therapies-for-dyslipidemia-management 2026-06-01T05:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-brain-decoding-of-spontaneous-pain-offers-path-to-objective-biomarkers-in-chronic-pain 2026-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/unraveling-the-mechanisms-of-cardiovascular-aging-from-molecular-drivers-to-therapeutic-strategies 2026-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abemaciclib-demonstrates-significant-efficacy-in-phase-3-trial-for-rare-dedifferentiated-liposarcoma 2026-05-31T21:40:03+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-erleada-shows-dramatic-efficacy-in-high-risk-prostate-cancer-surgery-trial 2026-05-31T21:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/circadian-timing-of-immunotherapy-may-influence-outcomes-in-triple-negative-breast-cancer-based-on-tumor-immune-microenvironment 2026-05-31T21:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/2026-china-nrdl-negotiations-record-submissions-pre-approval-access-and-the-rise-of-adcs-car-t-and-bispecific-antibodies 2026-05-31T21:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bemotrizinol-first-new-sunscreen-ingredient-in-over-20-years 2026-05-31T08:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/amivantamab-shows-unprecedented-response-rates-in-treatment-resistant-head-and-neck-cancer 2026-05-31T08:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bemotrizinol-for-sunscreens-as-dermatologists-warn-against-tanmaxxing-social-media-trend 2026-05-31T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/leflunomide-hydroxychloroquine-combination-shows-efficacy-in-systemic-sjogren-s-disease-in-phase-2b-trial 2026-05-30T22:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-a-dream-trial-41-of-exceptional-responders-remain-off-adt-at-18-months-in-metastatic-prostate-cancer 2026-05-30T21:20:32+00:00 hourly 0.9 https://trial.medpath.com/news/actinium-pharmaceuticals-secures-canadian-patent-protection-for-radiotherapy-programs-in-aml-and-cell-therapy-conditioning 2026-05-30T19:44:01+00:00 hourly 0.9 https://trial.medpath.com/news/scit-demonstrates-superior-igg4-and-treg-induction-versus-slit-in-house-dust-mite-allergy-study-finds 2026-05-30T19:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/senomac-trial-confirms-omitting-axillary-lymph-node-dissection-is-safe-for-breast-cancer-patients-with-sentinel-node-macrometastases 2026-05-30T19:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/cabometyx-shows-significant-efficacy-in-both-functional-and-non-functional-neuroendocrine-tumors 2026-05-30T19:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/implanted-radiation-tiles-double-survival-in-brain-metastasis-patients-phase-3-trial-shows 2026-05-30T19:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-recommends-eu-approval-of-roche-s-susvimo-first-continuous-delivery-treatment-for-neovascular-amd 2026-05-30T19:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-anselamimab-shows-62-survival-improvement-in-kappa-light-chain-amyloidosis-despite-missing-primary-endpoint 2026-05-30T19:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-s-lunbotinib-fumarate-shows-promising-phase-ii-results-in-ret-fusion-positive-nsclc 2026-05-30T19:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/tafasitamab-lenalidomide-combination-reduces-disease-progression-risk-by-25-in-high-risk-aggressive-b-cell-lymphomas 2026-05-30T19:27:55+00:00 hourly 0.9 https://trial.medpath.com/news/genomic-test-enables-thousands-of-breast-cancer-patients-to-safely-skip-chemotherapy 2026-05-30T19:22:45+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-s-centanafadine-shows-promise-for-executive-function-and-emotional-regulation-in-adult-adhd 2026-05-30T19:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/mannkind-corporation-receives-fda-approval-for-afrezza-inhaled-insulin-in-pediatric-diabetes-patients 2026-05-30T19:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/google-co-scientist-multi-agent-ai-system-validated-in-nature-preclinical-hypotheses-confirmed-in-aml-and-liver-fibrosis-public-registration-opens 2026-05-30T18:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/whitehawk-therapeutics-validates-sez6-as-high-expression-target-for-small-cell-lung-cancer-adc-development 2026-05-30T18:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/rybrevant-plus-lazcluze-achieves-nearly-3-5-year-median-overall-survival-in-atypical-egfr-mutated-nsclc 2026-05-30T18:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-biopharma-secures-patent-for-novel-coronavirus-treatment-targeting-viral-immune-suppression 2026-05-30T18:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/holmusk-expands-neuroblu-real-world-data-platform-to-46-million-patients-with-alzheimer-s-biomarker-and-neurological-outcomes-depth 2026-05-30T17:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/neuropace-receives-fda-approval-for-ai-powered-ecog-assistant-to-enhance-epilepsy-care 2026-05-30T13:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/asco-partners-with-ryght-ai-to-accelerate-site-selection-for-metastatic-breast-cancer-cdk4-6-inhibitor-trial 2026-05-30T13:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-july-2026-preview-key-decisions-spanning-oncology-nephrology-and-cardiology 2026-05-30T12:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/conexeu-sciences-initiates-preclinical-3d-bioprinted-breast-matrix-program-with-wake-forest-institute-for-regenerative-medicine 2026-05-30T05:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/rezdiffra-demonstrates-cardiovascular-and-liver-risk-reduction-in-mash-patients 2026-05-30T03:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-advances-first-in-class-quadruple-action-obesity-drug-ct-g32-into-primate-toxicology-studies 2026-05-30T03:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/exercise-in-early-to-middle-adulthood-may-slow-brain-aging-study-finds 2026-05-30T02:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-coredio-breakthrough-designation-for-ai-powered-heart-failure-monitoring-platform 2026-05-30T02:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/shine-technologies-secures-european-marketing-authorization-for-lutetium-177-radioisotope-ilumira 2026-05-30T02:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/most-favored-nation-drug-pricing-proposal-threatens-patient-access-and-pharmaceutical-innovation-experts-warn 2026-05-29T19:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharma-m-a-surge-drives-intensified-demand-for-specialized-legal-talent 2026-05-29T16:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/who-and-africa-cdc-prioritize-experimental-ebola-treatments-and-vaccines-for-bundibugyo-strain-amid-drc-outbreak 2026-05-29T15:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/pcos-officially-renamed-to-pmos-landmark-lancet-publication-caps-decade-long-global-consensus-process 2026-05-29T12:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/nucs-ai-partners-with-astrazeneca-to-develop-ai-driven-response-prediction-for-psma-targeted-radioconjugates 2026-05-29T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/biological-age-estimation-tools-show-promise-for-early-risk-detection-but-clinical-translation-requires-further-validation 2026-05-29T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-medication-when-and-how-blood-pressure-drugs-can-be-safely-reduced 2026-05-29T11:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/340b-drug-pricing-program-reform-california-s-opportunity-to-lead-on-transparency-and-accountability 2026-05-29T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/agios-pharmaceuticals-discontinues-blood-cancer-drug-tebapivat-after-phase-2-trial-failure 2026-05-29T11:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-and-france-launch-landmark-biomedical-and-ai-health-alliance-to-accelerate-research-on-major-diseases 2026-05-29T08:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-biologics-and-pfizer-forge-10-5-billion-strategic-collaboration-for-12-novel-cancer-programs 2026-05-29T08:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/mountain-valley-md-advances-quicksometm-sublingual-delivery-platform-for-compounded-peptides-reports-formulation-progress-across-bpc-157-retatrutide-and-others 2026-05-29T07:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/who-recommends-regeneron-s-maftivimab-for-clinical-trials-against-bundibugyo-ebolavirus-outbreak 2026-05-29T07:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/parexel-presents-real-world-safety-data-on-trastuzumab-deruxtecan-at-asco-2026 2026-05-29T07:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/parse-biosciences-and-bit-bio-form-strategic-alliance-to-map-cell-identity-for-ai-driven-drug-discovery 2026-05-29T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/bpgbio-to-present-phase-2-data-on-novel-mitochondrial-targeted-therapy-bpm31510-for-glioblastoma-at-asco-2026 2026-05-29T05:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/treos-bio-reports-six-year-cancer-free-survival-in-mss-mcrc-patient-treated-with-polypepi1018-off-the-shelf-immunotherapy 2026-05-29T05:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/procept-biorobotics-completes-water-iv-prostate-cancer-study-enrollment-receives-fda-approval-for-second-trial 2026-05-29T05:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/rest-therapeutics-receives-fda-clearance-for-first-in-human-trial-of-novel-early-ptsd-intervention-rst-101 2026-05-29T05:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/alzprotect-receives-fda-clearance-for-azp2006-in-progressive-supranuclear-palsy 2026-05-29T05:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/nuclidium-raises-eur115-million-to-advance-copper-based-radiotheranostics-for-prostate-and-breast-cancer 2026-05-29T05:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/delix-therapeutics-novel-neuroplastogen-zalsupindole-shows-no-cognitive-impairment-in-phase-1b-depression-trial 2026-05-29T04:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-panel-votes-to-update-covid-19-vaccines-to-target-xfg-variant-for-2026-2027-season 2026-05-29T03:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-therapeutics-receives-fda-priority-review-for-saroglitazar-in-primary-biliary-cholangitis 2026-05-29T03:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-sciences-initiates-first-clinical-trial-of-ai-designed-drug-formulation 2026-05-29T03:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/nestle-and-idb-holding-partner-to-bring-vowst-live-biotherapeutic-to-european-markets 2026-05-29T03:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-s-btk-inhibitor-orelabrutinib-receives-new-drug-application-acceptance-in-china-for-primary-immune-thrombocytopenia-treatment 2026-05-29T02:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/pepromene-bio-s-baff-r-car-t-therapy-shows-78-complete-response-rate-in-b-cell-lymphoma-patients-after-cd19-car-t-failure 2026-05-29T02:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-s-novel-sos1-inhibitor-lnp8701-shows-promising-safety-profile-in-phase-1-solid-tumor-trial 2026-05-29T02:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/salvectors-oncolytic-bacteria-therapy-yb1-x7-receives-dual-ind-clearance-in-us-and-china 2026-05-29T02:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/aptevo-and-niowave-form-strategic-partnership-to-develop-radiopharmaceutical-cancer-therapies 2026-05-29T00:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/repairon-s-engineered-heart-muscle-patches-show-promise-in-advanced-heart-failure-trial-published-in-nejm 2026-05-29T00:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/enterome-s-eo2463-receives-fda-orphan-drug-designation-for-watch-and-wait-indolent-non-hodgkin-lymphoma 2026-05-29T00:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/ai-transcription-tools-in-healthcare-navigating-the-legal-and-compliance-minefield 2026-05-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/octozi-raises-3m-to-deploy-agentic-ai-in-clinical-trial-data-operations-demonstrates-six-fold-throughput-gains 2026-05-28T22:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/secretome-therapeutics-secures-30-million-series-a-to-advance-cardiac-cell-therapy-for-duchenne-muscular-dystrophy 2026-05-28T22:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/aimedbio-invests-1-5-million-in-galaxy-for-ai-designed-brain-penetrating-antibody-development 2026-05-28T22:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/pet-imaging-in-alzheimer-disease-from-early-diagnosis-to-therapeutic-monitoring 2026-05-28T20:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/south-africa-s-afrigen-biologics-becomes-first-african-facility-to-receive-gmp-certification-for-mrna-manufacturing 2026-05-28T20:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/gene-solutions-receives-fda-breakthrough-device-designation-for-spot-mas-10-multi-cancer-blood-test 2026-05-28T20:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-three-breakthrough-breast-cancer-treatments-for-earlier-stage-disease 2026-05-28T20:23:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-pivekimab-sunirine-as-first-adc-for-ultra-rare-blood-cancer-bpdcn 2026-05-28T20:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-nejm-trial-provides-first-randomized-evidence-for-chiari-malformation-surgical-treatment 2026-05-28T20:23:32+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-review-raises-substantial-concern-that-vaping-may-increase-cancer-risk-over-time 2026-05-28T20:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-receives-ce-mark-for-first-dual-glucose-ketone-sensor-to-prevent-diabetic-ketoacidosis 2026-05-28T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/rectify-pharmaceuticals-reports-promising-preclinical-data-for-rty-406-in-primary-sclerosing-cholangitis-at-easl-2026 2026-05-28T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/viromissile-s-idov-safe-shows-30-46-response-rate-in-treatment-resistant-colorectal-cancer 2026-05-28T17:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-partners-with-colombia-on-260-million-vaccine-manufacturing-initiative 2026-05-28T17:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/verge-genomics-rebrands-as-verge-labs-following-als-drug-trial-failure-pivots-to-ai-driven-target-discovery 2026-05-28T17:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/solu-therapeutics-receives-fda-fast-track-designation-for-stx-0712-in-chronic-myelomonocytic-leukemia 2026-05-28T17:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/nielsen-biosciences-candin-achieves-primary-endpoint-in-first-phase-3-trial-for-common-warts-treatment 2026-05-28T16:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/indupro-doses-first-patient-in-phase-1-trial-of-proximity-based-bispecific-adc-idp-001-closes-77m-series-b 2026-05-28T16:12:47+00:00 hourly 0.9 https://trial.medpath.com/news/eom-pharmaceuticals-receives-fda-clearance-for-phase-2a-cancer-cachexia-trial-of-eom613 2026-05-28T16:11:05+00:00 hourly 0.9 https://trial.medpath.com/news/ember-lifesciences-secures-27m-series-a-funding-to-advance-cold-chain-technology-for-pharmaceutical-distribution 2026-05-28T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/therini-bio-initiates-phase-1b-trial-of-novel-anti-inflammatory-therapy-thn391-for-diabetic-macular-edema 2026-05-28T16:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-positions-ampligen-as-potential-ebola-treatment-following-who-emergency-declaration 2026-05-28T16:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/subtle-medical-receives-fda-clearance-for-subtlehd-pet-next-generation-ai-powered-image-acceleration-and-enhancement-software 2026-05-28T16:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/natera-s-signatera-becomes-first-pmda-approved-mrd-test-in-japan-for-colorectal-cancer 2026-05-28T16:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-advances-ttx-mc138-to-phase-2a-trial-following-successful-phase-1a-results-in-metastatic-cancer 2026-05-28T16:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/premia-and-lind-launch-joint-venture-to-transform-clinical-trial-enrollment-in-asia-pacific-with-ai-technology 2026-05-28T16:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-linzess-for-functional-constipation-in-children-as-young-as-2-years-old 2026-05-28T16:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-cardiac-monitoring-devices-market-to-reach-10-3-billion-by-2036-driven-by-rising-cardiovascular-disease-burden 2026-05-28T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fare-launches-10-million-mind-meld-team-grant-program-to-accelerate-translational-food-allergy-research 2026-05-28T14:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/atea-pharmaceuticals-advances-antiviral-pipeline-with-promising-drug-drug-interaction-data-and-first-in-class-hev-candidate 2026-05-28T14:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-reports-positive-phase-1-data-for-tnx-1500-anti-cd40l-antibody-in-transplant-rejection-prevention 2026-05-28T14:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/reprogram-biosciences-raises-6m-to-advance-mrna-tumor-cell-reprogramming-platform 2026-05-28T14:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-comprehensive-liver-disease-panel-to-transform-chronic-liver-disease-management 2026-05-28T14:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/tata-sons-backed-medtherapy-establishes-india-manufacturing-hub-for-car-t-cell-and-gene-therapies 2026-05-28T14:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/lifearc-partners-with-elpida-therapeutics-to-advance-gene-therapies-for-ultra-rare-pediatric-neurodegenerative-diseases 2026-05-28T14:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/umecrine-cognition-secures-sek-67-million-to-complete-phase-1b-2a-trial-of-golexanolone-for-pbc-related-fatigue 2026-05-28T14:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-completes-phase-2-trial-of-tipelukast-for-nafld-and-hypertriglyceridemia-in-type-2-diabetes 2026-05-28T13:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/noxopharm-s-sofra-platform-shows-200-fold-immune-activation-boost-in-cancer-research 2026-05-28T13:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/acurex-biosciences-awarded-asap-grant-to-advance-15-lo-targeting-approach-for-parkinson-s-disease 2026-05-28T13:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/imagion-biosystems-receives-fda-clearance-for-her2-targeted-mri-imaging-agent-trial 2026-05-28T11:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/the-next-era-of-biomanufacturing-will-be-won-by-intelligence-not-size 2026-05-28T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-combinations-show-dramatic-survival-gains-in-mesothelioma-patients 2026-05-28T09:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/kardigan-files-for-ipo-with-three-late-stage-cardiovascular-programs-targeting-unmet-medical-needs 2026-05-28T09:59:18+00:00 hourly 0.9 https://trial.medpath.com/news/biomunex-partners-with-ai-companies-to-accelerate-bispecific-antibody-discovery-in-cancer-immunotherapy 2026-05-28T07:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/depuy-synthes-secures-exclusive-distribution-rights-for-cgbio-s-growth-factor-bone-graft-substitute-novosis 2026-05-28T07:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/systemic-gene-therapy-syncav1-shields-brain-from-tdp-43-damage-by-fortifying-neuronal-resilience 2026-05-28T07:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/acrivon-therapeutics-reports-44-response-rate-for-chk1-2-inhibitor-acr-368-in-endometrial-cancer-phase-ii-trial 2026-05-28T07:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/b-well-connected-health-and-mytomorrows-partner-to-revolutionize-clinical-trial-patient-recruitment-through-ai-powered-data-integration 2026-05-28T07:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/vitamin-d-analog-paricalcitol-shows-promise-in-pancreatic-cancer-trial-by-reprogramming-tumor-microenvironment 2026-05-28T07:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/tga-expands-prescriber-access-for-psychedelic-assisted-therapy-boosting-emyria-s-clinical-network 2026-05-28T06:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/nodthera-s-nlrp3-inhibitor-ruvonoflast-shows-promising-anti-inflammatory-effects-in-cardiovascular-risk-patients 2026-05-28T05:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/ionetix-receives-first-anda-approval-for-gallium-ga-68-gozetotide-psma-pet-imaging-agent 2026-05-28T05:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/autobahn-therapeutics-receives-fda-fast-track-designation-for-elunetirom-in-bipolar-depression 2026-05-28T05:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/consano-bio-receives-fda-ind-clearance-for-c-1101-a-first-in-class-non-opioid-biologic-for-chronic-sciatica 2026-05-28T05:49:26+00:00 hourly 0.9 https://trial.medpath.com/news/hologic-s-breast-cancer-index-test-demonstrates-significant-impact-on-extended-endocrine-therapy-decisions-in-real-world-study 2026-05-28T05:49:22+00:00 hourly 0.9 https://trial.medpath.com/news/delphia-therapeutics-appoints-david-kerstein-as-cmo-to-advance-novel-activation-lethality-cancer-platform 2026-05-28T05:49:21+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-reports-durable-responses-with-unloxcyt-in-advanced-skin-cancer-at-asco-2026 2026-05-28T05:49:04+00:00 hourly 0.9 https://trial.medpath.com/news/new-proposal-signals-major-reforms-to-the-340b-drug-discount-program 2026-05-28T05:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-invests-3-83-billion-in-vaccine-platform-through-three-strategic-acquisitions 2026-05-28T03:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/former-palantir-executives-launch-perceptic-with-12m-to-unify-ai-driven-drug-discovery-platform 2026-05-28T03:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/bayescna-lowers-cancer-dna-detection-threshold-to-5-enabling-non-invasive-tumor-monitoring 2026-05-27T23:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/dapagliflozin-reduces-heart-failure-risk-by-82-in-carriers-of-cardiomyopathy-genetic-variants 2026-05-27T19:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/hyperfine-s-portable-mri-system-reduces-emergency-department-imaging-wait-times-by-over-6-hours-in-clinical-trial 2026-05-27T18:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/rogaratinib-achieves-41-7-response-rate-in-sdh-deficient-gist-demonstrating-breakthrough-efficacy-for-previously-untreatable-tumor-subtype 2026-05-27T18:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-opakalim-shows-promise-in-epilepsy-trials-with-superior-tolerability-profile 2026-05-27T18:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-therapeutics-triples-enrollment-in-phase-1b-trial-of-paxalisib-for-advanced-triple-negative-breast-cancer 2026-05-27T18:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/lucis-secures-20-million-series-a-to-scale-ai-powered-preventive-health-platform-across-europe 2026-05-27T18:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/neurovalens-receives-fda-de-novo-approval-for-ptsd-treatment-device-modius-spero 2026-05-27T18:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-shifts-policy-americans-with-ebola-at-kenya-facility-may-be-treated-in-the-united-states 2026-05-27T17:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-drug-like-molecules-that-directly-target-b-arrestins-discovered-opening-new-path-for-gpcr-targeted-therapies 2026-05-27T17:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-emerges-as-a-powerful-ally-in-the-fight-against-als-12-years-after-the-ice-bucket-challenge 2026-05-27T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/merz-therapeutics-partners-with-kvvit-to-bring-inbrija-parkinson-s-treatment-to-greater-china 2026-05-27T11:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/bial-completes-phase-2b-activate-study-of-potential-first-in-class-gba1-parkinson-s-treatment 2026-05-27T11:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-partners-with-teikoku-seiyaku-for-novel-rhmmp-7-therapy-manufacturing-to-treat-lumbar-disc-herniation 2026-05-27T11:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-devices-reveal-sleep-duration-linked-to-menstrual-cycle-regularity-large-scale-study-shows 2026-05-27T07:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/cloudbreak-b-receives-fda-clearance-for-cbt-199-ophthalmic-drug-trial-and-submits-ind-for-dry-eye-candidate-cbt-358 2026-05-27T01:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/entheon-biomedical-terminates-business-combination-with-nutravisor-receives-cad-350000-settlement 2026-05-27T00:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-class-3-1-classical-formula-drug-zhenwu-tang-granules-marking-tcm-modernization-milestone 2026-05-27T00:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/liquid-biopsy-reshapes-early-cancer-management-from-mrd-detection-to-cancer-interception 2026-05-26T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/the-tumor-microenvironment-as-a-driver-of-disease-progression-and-therapeutic-response-in-gynecological-malignancies 2026-05-26T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-grants-336804-rsus-to-three-new-employees-under-nasdaq-inducement-rule 2026-05-26T21:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/lung-cancer-is-no-longer-just-a-smoker-s-disease-the-case-for-broader-awareness-and-earlier-detection 2026-05-26T18:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/short-term-fasting-around-chemotherapy-improves-response-and-pfs-in-advanced-ovarian-cancer-pilot-trial 2026-05-26T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/four-year-match-trial-data-shows-70-transplant-free-survival-with-regenerative-macrophage-therapy-in-liver-cirrhosis 2026-05-26T06:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-for-ranibizumab-biosimilar-vislyfa-expanding-european-treatment-options-for-retinal-diseases 2026-05-26T06:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/macrophage-cell-therapy-shows-70-transplant-free-survival-rate-in-advanced-liver-disease-trial 2026-05-26T06:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/nfl-biosciences-achieves-30-higher-efficacy-than-champix-in-biomarker-positive-smoking-cessation-population 2026-05-26T06:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/ugandan-biotech-company-files-us-patent-for-multi-strain-ebola-mrna-vaccine-platform 2026-05-26T06:16:26+00:00 hourly 0.9 https://trial.medpath.com/news/obinutuzumab-b-mil62-shows-93-1-relapse-risk-reduction-in-phase-3-trial-for-aqp4-igg-nmosd 2026-05-26T06:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/biocardia-s-cardiamp-cell-therapy-shows-sustained-exercise-improvements-in-refractory-angina-patients 2026-05-26T06:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/menarini-group-to-present-comprehensive-oncology-data-at-asco-2026-featuring-elacestrant-combination-studies 2026-05-26T06:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-datroway-as-first-trop2-directed-adc-for-first-line-triple-negative-breast-cancer-treatment 2026-05-26T06:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-drug-regulator-recommends-discontinuation-of-crizanlizumab-following-failed-efficacy-trial 2026-05-26T06:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/treefrog-therapeutics-tfg-001-shows-rapid-dopamine-release-and-enhanced-reinnervation-in-parkinson-s-disease-models 2026-05-26T06:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/strainx-bioworks-raises-13-million-to-scale-precision-fermentation-platform-for-alternative-protein-production 2026-05-26T06:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/revvity-expands-precision-oncology-portfolio-with-new-cancer-test-launches-amid-steady-diagnostics-demand 2026-05-26T06:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/calibrating-microglia-states-in-alzheimer-s-disease-from-anti-amyloid-antibodies-to-multi-target-microenvironment-protection 2026-05-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sakar-healthcare-expands-oncology-reach-with-zydus-lifesciences-partnership-for-gcc-markets 2026-05-24T14:46:58+00:00 hourly 0.9 https://trial.medpath.com/news/semnur-pharmaceuticals-secures-100-million-strategic-investment-from-iholding-group-to-advance-non-opioid-pain-therapy-semdexa 2026-05-24T14:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/ultra-low-dose-immunotherapy-combination-demonstrates-superior-survival-in-metastatic-head-and-neck-cancer 2026-05-24T14:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/fulgent-genetics-reports-60-response-rate-for-fid-007-in-head-and-neck-cancer-phase-2-trial 2026-05-24T14:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-secures-fda-approval-for-generic-levothyroxine-sodium-tablets-in-1-87-billion-market 2026-05-24T14:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-launches-alastin-regenerative-skincare-brand-across-japan-and-asia-pacific-markets 2026-05-24T14:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/venus-remedies-secures-first-global-approval-for-plerixafor-in-saudi-arabia 2026-05-24T14:00:01+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-mrna-vaccine-shows-promise-against-three-ebola-virus-strains-in-preclinical-studies 2026-05-24T13:50:02+00:00 hourly 0.9 https://trial.medpath.com/news/akari-reports-breakthrough-preclinical-data-for-aktx-101-in-kras-mutated-pancreatic-cancer-stock-surges-50 2026-05-24T13:46:11+00:00 hourly 0.9 https://trial.medpath.com/news/bundibugyo-ebola-outbreak-in-drc-and-uganda-declared-public-health-emergency-of-international-concern 2026-05-24T13:46:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-ever-approval-for-hepatitis-delta-treatment-with-gilead-s-hepcludex 2026-05-24T13:44:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-prescription-to-otc-switch-for-adapalene-benzoyl-peroxide-acne-gel 2026-05-24T13:41:48+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-conditional-approval-for-vijoice-first-treatment-for-rare-pik3ca-related-overgrowth-disorders 2026-05-22T19:17:01+00:00 hourly 0.9 https://trial.medpath.com/news/vitrafy-s-no-wash-frozen-platelet-technology-achieves-94-recovery-rate-in-us-army-validation-study 2026-05-22T19:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-accelerates-velzatinib-phase-iii-trial-following-promising-first-line-gist-results 2026-05-22T19:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-foundationone-cdx-as-companion-diagnostic-for-tepotinib-in-met-exon-14-positive-nsclc 2026-05-22T19:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-s-astegolimab-copd-program-highlights-critical-trial-design-flaws-in-phase-3-confirmatory-studies 2026-05-22T18:58:33+00:00 hourly 0.9 https://trial.medpath.com/news/lupeng-pharmaceutical-s-fourth-generation-btk-inhibitor-rocbrutinib-approved-in-china-for-r-r-mcl-global-phase-3-rocket-cll-trial-underway 2026-05-22T18:55:10+00:00 hourly 0.9 https://trial.medpath.com/news/taimed-biologics-completes-phase-2b-enrollment-for-tmb-365-380-hiv-therapy-ahead-of-schedule 2026-05-22T18:53:03+00:00 hourly 0.9 https://trial.medpath.com/news/nuance-pharma-receives-nmpa-clearance-for-actair-r-phase-iii-trial-in-china 2026-05-22T18:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/trivarx-partners-with-beyond-drug-development-to-advance-novel-mri-based-cancer-imaging-technology 2026-05-22T18:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/858-therapeutics-parg-inhibitor-etx-19477-shows-57-orr-in-brca-mutated-ovarian-and-breast-cancer-earns-fda-fast-track-designation 2026-05-22T18:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/beta-bionics-targets-q2-2027-launch-for-mint-patch-pump-to-challenge-insulet-s-market-dominance 2026-05-22T18:42:06+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-shows-structured-yoga-program-significantly-reduces-mood-disturbance-anxiety-fatigue-and-insomnia-in-cancer-survivors 2026-05-22T18:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/regenxbio-and-abbvie-dose-first-patient-in-phase-iib-iii-naavigate-trial-of-one-time-gene-therapy-sura-vec-for-diabetic-retinopathy 2026-05-22T18:35:22+00:00 hourly 0.9 https://trial.medpath.com/news/ingenia-therapeutics-receives-krx-approval-for-ipo-as-tie2-targeted-therapies-advance-to-phase-3 2026-05-22T18:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/servier-to-present-long-term-voranigo-data-and-novel-adc-results-at-asco-2026 2026-05-22T18:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-and-verdinexor-combination-therapy-enters-canine-trial-for-pediatric-brain-cancer-treatment 2026-05-22T18:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-reports-strong-q1-2026-revenue-growth-driven-by-iqirvo-royalties-advances-pipeline-across-liver-disease-portfolio 2026-05-22T18:24:06+00:00 hourly 0.9 https://trial.medpath.com/news/manchester-biotech-imperagen-raises-ps5m-to-advance-quantum-ai-enzyme-engineering-platform 2026-05-22T18:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-car-t-therapy-faces-persistent-logistical-barriers-in-large-b-cell-lymphoma-treatment 2026-05-22T18:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-advances-two-major-clinical-programs-in-critical-care-and-cardiovascular-disease 2026-05-22T18:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/daraxonrasib-doubles-overall-survival-in-metastatic-pancreatic-cancer-highlighted-at-asco-2025 2026-05-22T18:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/oddifact-secures-european-orphan-drug-designation-for-infliximab-in-kawasaki-disease 2026-05-22T18:12:43+00:00 hourly 0.9 https://trial.medpath.com/news/outcomes4me-acquires-ai-powered-platforms-to-enhance-cancer-patient-access-to-clinical-trials 2026-05-22T18:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/massive-bio-and-beekeeperai-deploy-privacy-preserving-ai-to-expand-cancer-trial-access-in-underserved-communities 2026-05-22T18:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/grundium-acquires-visiopharm-to-create-integrated-ai-driven-precision-pathology-platform 2026-05-22T18:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/liminatus-pharma-to-acquire-innocsai-in-320-million-deal-gaining-next-generation-car-t-pipeline-for-hematologic-and-solid-tumors 2026-05-22T18:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/amr-bio-launches-with-phase-iii-ready-antimicrobial-xf-73-to-combat-post-surgical-infections 2026-05-22T17:53:41+00:00 hourly 0.9 https://trial.medpath.com/news/remote-blood-sampling-technology-shows-promise-for-alzheimer-s-disease-biomarker-testing 2026-05-22T17:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/concept-life-sciences-and-openbench-launch-ai-driven-success-based-drug-discovery-partnership 2026-05-22T17:46:52+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-sintilimab-fruquintinib-combination-for-advanced-renal-cell-carcinoma 2026-05-22T17:45:23+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-acquires-spr-therapeutics-for-650m-to-expand-pain-management-portfolio 2026-05-22T17:43:38+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-reports-positive-phase-1-2-data-for-ozekibart-in-colorectal-cancer-plans-fda-filing-for-chondrosarcoma 2026-05-22T17:41:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-and-orphan-drug-designations-to-fl118-for-osteosarcoma-treatment 2026-05-22T17:40:36+00:00 hourly 0.9 https://trial.medpath.com/news/grey-matters-takes-delivery-of-first-brain-dedicated-pet-scanner-for-novascan-neuroimaging-clinic-in-florida 2026-05-22T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/insphero-acquires-phenovista-biosciences-to-strengthen-3d-drug-testing-platform 2026-05-22T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/recode-therapeutics-achieves-first-clinical-proof-of-mrna-therapy-activity-in-primary-ciliary-dyskinesia 2026-05-22T17:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/ryvu-therapeutics-advances-small-molecule-oncology-pipeline-with-european-investment-bank-financing-and-partnership-strategy 2026-05-22T17:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/histosonics-edison-histotripsy-system-earns-taiwan-fda-approval-for-non-invasive-liver-tumor-treatment 2026-05-22T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-faces-mixed-results-in-patent-challenges-against-genzyme-s-gene-therapy-analytical-methods 2026-05-22T17:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/ichnos-glenmark-innovation-unveils-first-in-class-multispecific-cancer-drug-isb-2301-for-solid-tumors 2026-05-22T17:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/in-utero-gene-therapy-approaches-first-fda-trial-after-25-years-of-development 2026-05-22T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/qihan-biotech-receives-fda-ind-clearance-for-qt-019c-universal-car-t-therapy-targeting-autoimmune-diseases 2026-05-22T17:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/oorja-bio-launches-with-30m-to-develop-novel-regenerative-therapy-for-idiopathic-pulmonary-fibrosis 2026-05-22T17:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/23andme-partners-with-healthex-to-launch-ai-powered-health-summary-integrating-genetic-and-medical-data 2026-05-22T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/flow-pharma-receives-patent-allowance-for-universal-ebola-treatment-using-siltuximab 2026-05-22T17:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-researchers-launch-largest-fmt-trial-to-enhance-lung-cancer-immunotherapy 2026-05-22T17:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/tocilizumab-shows-promise-as-immunotherapy-for-treatment-resistant-depression-in-pilot-trial 2026-05-22T17:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-speech-assessment-detects-alzheimer-s-pathology-through-automated-phone-calls 2026-05-22T16:59:59+00:00 hourly 0.9 https://trial.medpath.com/news/haya-therapeutics-doses-first-patients-in-phase-1-trial-of-htx-001-for-cardiac-fibrosis 2026-05-22T16:59:38+00:00 hourly 0.9 https://trial.medpath.com/news/collaborative-drug-discovery-partners-with-eli-lilly-to-integrate-ai-ml-models-into-cdd-vault-platform 2026-05-22T16:56:07+00:00 hourly 0.9 https://trial.medpath.com/news/continuity-biosciences-initiates-first-in-human-trial-of-iontophoretic-drug-delivery-platform-for-pancreatic-cancer 2026-05-22T16:55:20+00:00 hourly 0.9 https://trial.medpath.com/news/sarah-cannon-research-institute-partners-with-pfizer-to-accelerate-community-based-oncology-trials 2026-05-22T16:52:41+00:00 hourly 0.9 https://trial.medpath.com/news/from-dysbiosis-to-precision-medicine-targeting-the-microbial-metabolic-axis-in-ibd-management 2026-05-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oura-files-confidentially-for-us-ipo-as-smart-ring-health-platform-targets-2-billion-revenue 2026-05-21T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/surgeon-general-advisory-warns-excessive-screen-use-is-a-top-public-health-threat-for-children-and-adolescents 2026-05-21T16:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/antag-therapeutics-first-in-class-gipr-antagonist-at7687-shows-promising-phase-1-results-and-preclinical-combination-data-at-ada-2026 2026-05-21T11:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/ayvakit-avapritinib-high-response-rates-in-rare-cancers-and-mastocytosis-with-critical-safety-monitoring-requirements 2026-05-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/one-biosciences-secures-pscc-boost-funding-to-develop-first-single-cell-assay-for-adc-therapies-in-oncology 2026-05-20T09:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-dysport-shows-superior-duration-over-botox-in-first-head-to-head-spasticity-trial 2026-05-20T09:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/matter-bio-files-first-ind-for-listeria-based-immunotherapy-targeting-pancreatic-cancer 2026-05-20T09:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/dynamx-bioadaptor-shows-88-reduction-in-cardiovascular-death-compared-to-drug-eluting-stents-in-four-year-trial 2026-05-20T09:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/mabylon-advances-my006-peanut-allergy-treatment-to-phase-ib-following-positive-safety-data 2026-05-20T09:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/century-health-raises-5m-seed-round-as-ai-platform-achieves-97-accuracy-in-clinical-data-abstraction 2026-05-20T09:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/oorja-bio-launches-with-30m-series-a-to-advance-novel-ipf-therapy-orj-001 2026-05-20T09:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-cellular-dynamics-opens-200-million-ipsc-manufacturing-facility-to-quadruple-production-capacity 2026-05-20T09:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-glaucoma-drug-pdp-716-receives-fda-complete-response-letter-due-to-manufacturing-facility-issues 2026-05-20T09:00:07+00:00 hourly 0.9 https://trial.medpath.com/news/mentari-therapeutics-goes-public-through-421m-reverse-merger-to-advance-novel-pacap-targeting-migraine-therapies 2026-05-20T08:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/risen-pharma-initiates-phase-2-trial-of-rp902-for-alzheimer-s-disease-in-china 2026-05-20T08:55:28+00:00 hourly 0.9 https://trial.medpath.com/news/dropshot-therapeutics-advances-renal-disease-program-to-clinical-stage-using-etherna-s-mrna-platform 2026-05-20T08:53:39+00:00 hourly 0.9 https://trial.medpath.com/news/blank-bio-secures-7-2m-seed-funding-and-pacbio-partnership-to-advance-rna-foundation-models-for-precision-oncology 2026-05-20T08:51:39+00:00 hourly 0.9 https://trial.medpath.com/news/mekanistic-therapeutics-receives-fda-clearance-for-first-in-class-dual-pi3k-egfr-inhibitor-mtx-531 2026-05-20T08:51:29+00:00 hourly 0.9 https://trial.medpath.com/news/matisse-pharmaceuticals-receives-fda-ind-clearance-for-novel-sepsis-treatment-isupartob-sodium 2026-05-20T08:51:18+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-partners-with-merck-for-phase-3-colorectal-cancer-trial-combining-zanzalintinib-with-keytruda 2026-05-20T08:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/accro-bioscience-secures-50m-series-c-to-advance-ripk2-inhibitor-ac-101-for-ulcerative-colitis 2026-05-20T08:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/sandboxaq-to-bring-physics-grounded-drug-discovery-models-to-google-cloud-marketplace 2026-05-20T08:47:05+00:00 hourly 0.9 https://trial.medpath.com/news/proencia-biotechnology-secures-pre-seed-funding-to-advance-novel-periodontal-disease-treatment-pipeline 2026-05-20T08:45:52+00:00 hourly 0.9 https://trial.medpath.com/news/cyclana-bio-launches-500-patient-study-to-decode-endometriosis-mechanisms-using-novel-tissue-based-approach 2026-05-20T08:44:42+00:00 hourly 0.9 https://trial.medpath.com/news/neurodiscovery-ai-launches-neuroterminal-platform-to-accelerate-neurological-clinical-trial-recruitment 2026-05-20T08:44:24+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-launches-pivotal-phase-2-3-revival-trial-of-pivekimab-sunirine-in-first-line-aml-expands-into-pediatric-setting 2026-05-20T08:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/hephaistos-pharma-appoints-stephan-braun-as-chief-medical-officer-to-advance-tlr4-agonist-hepha440-toward-clinical-trials 2026-05-20T08:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/cullinan-therapeutics-receives-fda-orphan-drug-designation-for-novel-flt3xcd3-t-cell-engager-cln-049-in-relapsed-refractory-aml 2026-05-20T08:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-s-seismiq-4ce-coronary-lithotripsy-catheter-meets-primary-endpoints-in-pivotal-fracture-trial 2026-05-20T08:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-experimental-alpha-1-antitrypsin-therapy-outperforms-standard-care-in-phase-3-trial 2026-05-20T08:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-faces-885-million-antitrust-verdict-for-delaying-generic-constipation-drug-amitiza 2026-05-20T07:57:10+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-efdoralprin-alfa-demonstrates-superior-efficacy-over-standard-care-in-alpha-1-antitrypsin-deficiency-phase-2-trial 2026-05-20T07:55:18+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-to-present-96-week-data-from-phase-2-solstice-trial-for-chronic-hepatitis-delta-at-easl-congress-2026 2026-05-20T07:53:35+00:00 hourly 0.9 https://trial.medpath.com/news/ms-pharma-secures-strategic-investment-from-olayan-financing-company-to-accelerate-mena-biosimilars-expansion 2026-05-20T07:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/mesenchymal-stem-cell-therapy-shows-promise-for-rare-butterfly-skin-disease-in-spanish-clinical-trial 2026-05-20T07:47:26+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-tezepelumab-efficacy-in-underrepresented-severe-asthma-populations 2026-05-20T07:45:07+00:00 hourly 0.9 https://trial.medpath.com/news/roche-partners-with-un-backed-group-to-expand-global-access-to-influenza-drug-xofluza 2026-05-20T07:42:01+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-reports-positive-phase-2a-results-for-lam-001-in-pulmonary-hypertension 2026-05-20T07:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/mavodelpar-shows-promise-in-phase-1-trial-for-primary-mitochondrial-myopathy 2026-05-20T07:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/12-year-old-becomes-first-indiana-patient-to-receive-fda-approved-gene-therapy-for-beta-thalassemia 2026-05-20T07:37:39+00:00 hourly 0.9 https://trial.medpath.com/news/hedge-fund-adar1-capital-invests-37-million-in-crinetics-pharmaceuticals-following-palsonify-launch 2026-05-20T07:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biological-launches-xpressmax-cell-free-protein-synthesis-kit-for-ai-driven-antibody-discovery 2026-05-20T07:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/illuminare-biotechnologies-advances-nerve-visualization-drug-illuminare-1-to-phase-ii-trial-following-successful-phase-i-results 2026-05-20T07:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/bracco-s-vueject-receives-fda-510-k-clearance-and-health-canada-authorization-as-first-dedicated-ultrasound-contrast-delivery-system-for-cardiology-imaging 2026-05-20T07:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-invests-1-5-billion-in-mirus-for-revolutionary-nickel-free-tavr-technology 2026-05-20T07:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-azd3470-shows-promise-in-first-in-human-trial-for-relapsed-refractory-hodgkin-lymphoma 2026-05-20T07:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/who-prepares-clinical-trial-of-experimental-ebola-treatments-as-bundibugyo-outbreak-spreads-across-central-africa 2026-05-20T07:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-acquires-orphai-for-187m-to-advance-inhaled-rapamycin-pipeline-for-rare-pulmonary-diseases 2026-05-20T07:28:40+00:00 hourly 0.9 https://trial.medpath.com/news/tricelx-files-first-cell-therapy-ind-for-chronic-traumatic-encephalopathy-with-dual-fda-designations 2026-05-20T07:18:07+00:00 hourly 0.9 https://trial.medpath.com/news/oral-pv-10-shows-promising-anti-tumor-activity-in-preclinical-bladder-cancer-study 2026-05-20T07:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/uk-mhra-approves-vyjuvek-gene-therapy-for-dystrophic-epidermolysis-bullosa-from-birth 2026-05-20T07:15:22+00:00 hourly 0.9 https://trial.medpath.com/news/children-s-mercy-partners-with-basepath-health-to-scale-cell-and-gene-therapy-access-for-pediatric-patients 2026-05-20T07:15:11+00:00 hourly 0.9 https://trial.medpath.com/news/triveni-bio-initiates-phase-1-trial-of-dual-target-bispecific-antibody-triv-573-for-atopic-dermatitis 2026-05-20T07:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-s-bmn-401-shows-mixed-results-in-phase-3-trial-for-rare-enpp1-deficiency 2026-05-20T07:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-ver-01-first-in-class-cannabis-based-treatment-for-chronic-low-back-pain 2026-05-20T07:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/prilenia-withdraws-european-application-for-huntington-s-disease-drug-pridopidine-after-regulatory-rejection 2026-05-20T07:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-partners-with-botanix-to-secure-supply-chain-for-fda-approved-hyperhidrosis-treatment-sofdra 2026-05-20T07:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/elanco-launches-befrena-new-anti-il-31-monoclonal-antibody-for-canine-allergic-dermatitis 2026-05-20T07:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-and-genesis-expand-ai-drug-discovery-partnership-in-120m-deal 2026-05-19T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-blueprint-medicines-ayvakyt-for-advanced-systemic-mastocytosis-on-nhs 2026-05-18T14:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/cellogen-therapeutics-secures-2-4m-to-advance-affordable-car-t-cancer-therapies-in-india 2026-05-18T13:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/vincentage-pharma-s-oral-glp-1-agonist-vct220-achieves-12-weight-loss-in-pivotal-phase-3-trial 2026-05-18T13:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/parsortix-ctc-platform-demonstrates-feasibility-for-adc-target-assessment-in-breast-and-ovarian-cancers 2026-05-18T13:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-s-alecensa-receives-world-s-first-tumor-agnostic-approval-for-alk-fusion-positive-solid-tumors 2026-05-18T13:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-secures-orphan-drug-designation-in-japan-for-novel-acth-targeting-antibody-asedebart 2026-05-18T13:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/danish-biotech-alcolase-raises-eur1-5m-to-develop-enzyme-treatment-for-alcohol-intolerance-in-east-asia 2026-05-18T12:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/prokarium-s-zh9-shows-91-freedom-from-relapse-in-phase-1-1b-trial-for-non-muscle-invasive-bladder-cancer 2026-05-18T12:59:19+00:00 hourly 0.9 https://trial.medpath.com/news/lotte-biologics-expands-manufacturing-partnership-with-ottimo-pharma-for-biparatopic-antibody-development 2026-05-18T12:58:55+00:00 hourly 0.9 https://trial.medpath.com/news/cosmo-completes-phase-ii-enrollment-for-novel-rifamycin-enema-in-distal-ulcerative-colitis 2026-05-18T12:57:46+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-s-ai-designed-let003-shows-superior-obesity-treatment-potential-in-preclinical-studies 2026-05-18T12:53:14+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-and-revolution-medicines-forge-strategic-partnership-to-bring-breakthrough-pancreatic-cancer-therapy-to-asia 2026-05-18T12:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/stereotactic-ablative-body-radiotherapy-achieves-100-local-control-in-primary-kidney-cancer-fastrack-ii-final-results 2026-05-18T12:46:22+00:00 hourly 0.9 https://trial.medpath.com/news/organabio-acquires-excellos-assets-to-create-bicoastal-cell-therapy-manufacturing-network 2026-05-18T12:29:24+00:00 hourly 0.9 https://trial.medpath.com/news/impact-td-registry-reveals-stark-diagnostic-gap-only-23-of-young-adults-with-mood-disorders-and-tardive-dyskinesia-symptoms-receive-formal-diagnosis 2026-05-18T12:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-neuroscience-harnessing-ai-and-multi-omics-to-bridge-lab-discoveries-and-clinical-solutions-for-neurodegenerative-disorders 2026-05-18T03:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-once-monthly-oral-prep-pill-mk-8527-enters-phase-3-trial-enrolling-high-risk-populations-in-newark 2026-05-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/select-early-stage-breast-cancer-patients-achieve-complete-response-without-surgery-following-ablative-radiation-and-endocrine-therapy 2026-05-16T22:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/y-mabs-therapeutics-restructures-pipeline-following-fda-rejection-of-neuroblastoma-drug-omburtamab 2026-05-16T22:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-expands-nurtec-odt-migraine-program-with-korean-real-world-study-and-new-tablet-formulation 2026-05-16T22:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/jasper-therapeutics-advances-targeted-antibody-conditioning-platform-for-stem-cell-transplants-and-gene-therapies 2026-05-16T22:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/xbiotech-launches-phase-ii-trial-of-vilamakitug-for-active-axial-spondyloarthritis-following-fda-clearance 2026-05-16T22:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-pharmaceutical-company-warns-against-tavneos-use-after-20-deaths-linked-to-severe-liver-dysfunction 2026-05-16T22:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-fianlimab-cemiplimab-combination-misses-primary-endpoint-in-phase-3-melanoma-trial 2026-05-16T21:59:57+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-shows-promise-for-pembrolizumab-lenvatinib-combination-in-mucosal-melanoma 2026-05-16T21:58:14+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-receives-fda-clearance-for-first-human-trial-of-genetically-modified-pig-heart-transplant 2026-05-16T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-therapy-shows-promise-for-alzheimer-s-disease-in-combination-trial 2026-05-16T21:49:40+00:00 hourly 0.9 https://trial.medpath.com/news/kh607-meets-primary-endpoint-in-phase-2b-trial-for-major-depressive-disorder 2026-05-16T21:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/favipiravir-shows-50-mortality-reduction-in-first-randomized-lassa-fever-trial-in-four-decades 2026-05-16T21:18:14+00:00 hourly 0.9 https://trial.medpath.com/news/valirx-secures-ps1-16m-funding-to-advance-cancer-therapeutics-and-women-s-health-pipeline 2026-05-16T21:17:49+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-s-ligufalimab-shows-promising-phase-ii-results-in-frontline-aml-treatment 2026-05-16T21:17:01+00:00 hourly 0.9 https://trial.medpath.com/news/iqirvo-shows-promising-real-world-results-for-primary-biliary-cholangitis-at-easl-2026 2026-05-16T21:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/alteogen-receives-korean-approval-for-aflibercept-biosimilar-targeting-growing-retinal-disease-market 2026-05-16T21:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/congo-s-17th-ebola-outbreak-bundibugyo-strain-confirmed-as-death-toll-reaches-80 2026-05-15T07:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/ninamed-secures-13-75m-to-advance-non-invasive-overactive-bladder-therapy-targeting-550-million-patients 2026-05-15T06:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/edap-and-telix-partner-to-advance-precision-prostate-cancer-treatment-through-hifu-psma-pet-integration 2026-05-15T06:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/sn-bioscience-initiates-global-phase-1b-2-trial-of-snb-101-for-small-cell-lung-cancer-with-zero-high-grade-diarrhea-events 2026-05-15T06:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/valion-bio-s-velocity-bioworks-secures-exclusive-license-for-next-generation-nmr-diagnostic-platform 2026-05-15T06:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-launches-clinical-studies-to-evaluate-multi-cancer-early-detection-tests-in-asian-populations 2026-05-15T06:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/massive-bio-and-gell-announce-strategic-partnership-to-advance-ai-driven-precision-oncology-across-latin-america-and-the-united-states 2026-05-15T06:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/voxcell-bioinnovation-and-admare-partner-to-validate-bioprinted-cancer-models-for-antibody-therapy-development 2026-05-15T05:58:21+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-recalls-doxorubicin-liposome-injection-due-to-glass-particle-contamination 2026-05-15T05:57:24+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-topaz-trial-finds-bone-density-drugs-do-not-prevent-fractures-in-brittle-bone-disease 2026-05-15T05:56:58+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-drug-shows-promise-for-treatment-resistant-uterine-cancer-in-phase-ii-trial 2026-05-15T05:55:19+00:00 hourly 0.9 https://trial.medpath.com/news/datar-cancer-genetics-receives-us-fda-clearance-for-celldx-tissue-comprehensive-genomic-profiling-assay 2026-05-15T05:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/nuwellis-advances-pediatric-expansion-of-aquadex-system-following-fda-pre-submission-meeting 2026-05-15T05:44:51+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-receives-fda-fast-track-designation-for-xpro1595-in-early-alzheimer-s-disease 2026-05-15T05:41:01+00:00 hourly 0.9 https://trial.medpath.com/news/sonomotion-s-break-wave-lithotripsy-device-meets-pivotal-trial-endpoints-receives-fda-clearance 2026-05-15T05:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/mezzion-secures-strategic-financing-to-advance-phase-3-trial-of-udenafil-for-fontan-circulation 2026-05-15T05:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-files-for-japanese-approval-of-sparsentan-for-iga-nephropathy-citing-significant-proteinuria-reduction 2026-05-15T05:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/nevian-life-science-achieves-historic-milestone-with-first-bangladeshi-pharmaceutical-exports-to-canada 2026-05-15T05:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/create-medicines-raises-122-million-to-advance-in-vivo-car-t-therapies-for-cancer-and-autoimmune-diseases 2026-05-15T05:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-develops-brain-penetrating-odf-formulation-of-scd1-inhibitor-aramchol-for-parkinson-s-disease 2026-05-15T05:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-tests-novel-immunotherapy-chemotherapy-sequence-for-high-risk-diffuse-large-b-cell-lymphoma 2026-05-15T05:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/ema-wellness-and-mira-analytics-form-exclusive-partnership-to-deploy-ai-driven-endpoint-validation-in-cns-clinical-trials 2026-05-15T05:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/eyepoint-s-duravyu-eye-drug-clears-safety-review-late-stage-trials-to-continue 2026-05-15T05:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-s-tau-targeting-alzheimer-s-drug-shows-promise-despite-missing-primary-endpoint-in-phase-2-study 2026-05-15T05:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-l1-79-shows-promising-results-for-core-autism-symptoms-in-adolescent-trial 2026-05-15T05:25:33+00:00 hourly 0.9 https://trial.medpath.com/news/cuhk-completes-first-clinical-trial-of-glp-1-diabetes-drug-for-severe-stroke-recovery 2026-05-15T05:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/medipost-s-cartistem-achieves-all-primary-endpoints-in-japan-phase-3-trial-for-knee-osteoarthritis 2026-05-15T05:23:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tessie-tasipimidine-for-canine-noise-aversion-and-separation-anxiety 2026-05-15T05:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-unveils-corabotase-first-in-class-recombinant-neuroinhibitor-for-aesthetic-applications 2026-05-15T05:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/bain-backed-tanabe-pharma-targets-three-new-drug-launches-annually-in-japan-led-by-rare-disease-candidate 2026-05-15T05:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/gccl-and-gempharmatech-forge-strategic-alliance-to-bridge-non-clinical-and-clinical-drug-development 2026-05-15T05:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/spark-biomedical-appoints-anja-krammer-as-ceo-to-drive-bioelectronic-medicine-platform-forward 2026-05-15T05:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-gene-therapy-khn921-for-hypertrophic-cardiomyopathy-phase-i-ii-trial 2026-05-15T04:57:44+00:00 hourly 0.9 https://trial.medpath.com/news/major-anti-aging-drug-development-setbacks-reveal-new-opportunities-for-precision-medicine-approaches 2026-05-15T04:56:36+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-s-genio-system-drives-22-sequential-u-s-revenue-growth-in-q2-2026-secures-110-million-financing 2026-05-15T04:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/curium-knocks-out-novartis-cancer-drug-patents-in-generics-fight 2026-05-15T04:49:39+00:00 hourly 0.9 https://trial.medpath.com/news/qureight-partners-with-mediar-therapeutics-to-deploy-ai-powered-imaging-analytics-in-phase-2-systemic-sclerosis-trial 2026-05-15T04:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/merit-and-mti-form-strategic-partnership-to-revolutionize-spirometry-data-collection-in-clinical-trials 2026-05-15T04:48:33+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-affirms-noninfringement-ruling-in-actelion-mylan-hypertension-drug-patent-dispute 2026-05-15T04:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-khn921-gene-therapy-trial-for-mybpc3-associated-hypertrophic-cardiomyopathy 2026-05-15T04:47:05+00:00 hourly 0.9 https://trial.medpath.com/news/catalent-partners-with-elpida-therapeutics-to-advance-aav-gene-therapy-for-ultra-rare-spg50-disease 2026-05-15T04:43:08+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-unveils-next-generation-obesity-pipeline-at-ada-2026-featuring-oral-daily-and-weekly-glp-1-candidates-amylin-analog-and-inhbe-sirna 2026-05-15T04:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/andera-partners-leads-20-million-series-d-for-rivermark-medical-s-bph-device-therapy 2026-05-15T04:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-strengthens-safety-warnings-for-finasteride-and-dutasteride-over-psychiatric-and-sexual-side-effects 2026-05-15T04:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/nexentis-subsidiary-mitocarex-achieves-drug-discovery-milestone-with-mitoline-r-platform-for-cancer-and-inflammatory-disease-treatment 2026-05-15T04:16:22+00:00 hourly 0.9 https://trial.medpath.com/news/nvision-raises-55m-to-advance-quantum-enhanced-cancer-imaging-and-drug-development-platform 2026-05-15T04:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/zenas-biopharma-initiates-phase-1-trial-of-zb021-first-oral-il-17-inhibitor-for-autoimmune-diseases 2026-05-15T04:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/veristat-launches-ai-powered-biostatistics-platform-to-accelerate-clinical-trial-data-analysis 2026-05-15T04:01:19+00:00 hourly 0.9 https://trial.medpath.com/news/uae-becomes-first-country-to-approve-astrazeneca-s-baxfendy-for-resistant-hypertension 2026-05-15T04:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/andzonbio2-partners-with-cambridge-to-develop-first-in-class-neuroinflammation-therapeutics 2026-05-15T03:58:06+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-partners-with-astrazeneca-and-gsk-on-ai-driven-oncology-research-collaborations 2026-05-15T03:54:39+00:00 hourly 0.9 https://trial.medpath.com/news/ektah-s-novel-obesity-drug-shows-promise-in-reducing-weight-rebound-after-glp-1-treatment-discontinuation 2026-05-15T03:45:54+00:00 hourly 0.9 https://trial.medpath.com/news/neurocatch-partners-with-geneva-foundation-to-advance-military-cognitive-health-research 2026-05-15T03:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-challenges-traditional-view-of-thyroid-eye-disease-progression 2026-05-15T03:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/vicentra-scales-kaleido-insulin-patch-pump-production-triples-manufacturing-capacity 2026-05-15T03:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/aquestive-therapeutics-secures-150-million-debt-refinancing-to-support-anaphylm-launch-preparations 2026-05-15T03:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/novel-anti-hiv-car-t-cell-therapy-shows-promise-for-durable-viral-control-in-early-clinical-trial 2026-05-15T03:27:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rare-disease-evidence-principles-eligibility-to-repair-biotechnologies-mrna-therapy-for-homozygous-familial-hypercholesterolemia 2026-05-15T03:16:45+00:00 hourly 0.9 https://trial.medpath.com/news/dare-bioscience-reports-positive-interim-phase-3-results-for-ovaprene-hormone-free-contraceptive 2026-05-15T03:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/halia-therapeutics-reports-67-hematological-improvement-rate-with-ofirnoflast-in-lower-risk-mds-phase-2-trial 2026-05-15T03:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-emiltatug-ledadotin-for-adenoid-cystic-carcinoma 2026-05-15T03:02:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-ever-clearance-for-continuous-ai-sepsis-monitoring-system 2026-05-15T03:01:41+00:00 hourly 0.9 https://trial.medpath.com/news/enterome-s-eo2463-shows-promising-cd8-t-cell-expansion-in-phase-2-indolent-non-hodgkin-lymphoma-trial 2026-05-15T02:59:44+00:00 hourly 0.9 https://trial.medpath.com/news/enterprise-therapeutics-etd001-demonstrates-significant-lung-function-improvement-in-phase-2-cystic-fibrosis-trial 2026-05-15T02:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/infex-therapeutics-secures-ps4-3m-to-advance-anti-virulence-therapy-resp-x-following-phase-2a-trial-completion 2026-05-15T02:54:35+00:00 hourly 0.9 https://trial.medpath.com/news/astronautx-appoints-dr-michelle-mellion-as-cmo-to-lead-novel-sleep-based-alzheimer-s-therapeutics-into-clinical-development 2026-05-15T02:50:13+00:00 hourly 0.9 https://trial.medpath.com/news/justice-department-charges-455-in-6-5-billion-healthcare-fraud-sweep-spotlighting-cardiovascular-screening-scheme 2026-05-14T22:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardinal-health-demonstrates-strong-financial-momentum-amid-evolving-pharmaceutical-distribution-landscape 2026-05-14T20:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/focal-therapy-for-localized-prostate-cancer-promise-progress-and-unanswered-questions 2026-05-14T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/prescriptions-for-unproven-cancer-treatment-surge-250-after-mel-gibson-s-endorsement-on-joe-rogan-podcast 2026-05-13T14:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/kailera-and-hengrui-present-promising-ribupatide-data-at-ada-2026-demonstrating-strong-weight-loss-efficacy 2026-05-13T11:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/mira-pharmaceuticals-skny-1-shows-promising-oral-bioavailability-and-brain-penetration-in-preclinical-obesity-and-addiction-studies 2026-05-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-cas-systems-emerge-as-programmable-weapons-against-mrsa-biofilms 2026-05-12T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/alignment-healthcare-doubles-net-income-as-medicare-advantage-medical-costs-ease 2026-05-12T22:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/syndax-presents-comprehensive-revuforj-data-at-major-oncology-conferences-highlighting-post-transplant-efficacy 2026-05-12T14:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-cancer-vaccine-market-to-surpass-1-20-billion-in-2026-as-personalized-oncology-gains-momentum 2026-05-12T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/ceribell-reports-29-revenue-growth-in-q1-2026-launches-neonate-and-pediatric-eeg-products 2026-05-12T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/hydrocortisone-linked-to-65-lower-mortality-in-severe-cap-while-other-corticosteroids-show-no-benefit 2026-05-12T07:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/delos-capital-and-ap-biosciences-launch-strategic-partnership-to-accelerate-next-generation-antibody-development 2026-05-12T07:54:56+00:00 hourly 0.9 https://trial.medpath.com/news/macrogenics-sells-gmp-manufacturing-operations-to-bora-pharmaceuticals-for-122-5-million 2026-05-12T07:52:02+00:00 hourly 0.9 https://trial.medpath.com/news/aldevron-and-minaris-renew-strategic-partnership-to-accelerate-gene-modified-cell-therapy-development 2026-05-12T07:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-flu-vaccine-shows-27-efficacy-improvement-in-major-clinical-trial 2026-05-12T07:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/obinutuzumab-b-cell-depletion-significantly-reduces-corticosteroid-requiring-chronic-gvhd-in-phase-ii-trial 2026-05-12T07:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/anaveon-presents-positive-anv600-clinical-data-at-asco-2026-seeks-partners-for-oncology-portfolio 2026-05-12T07:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/transpire-bio-achieves-fda-filing-acceptance-for-generic-high-strength-trelegy-ellipta-with-potential-180-day-market-exclusivity 2026-05-12T07:35:38+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-to-acquire-nuvalent-for-10-6-billion-in-major-lung-cancer-pipeline-expansion 2026-05-12T07:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/cellular-intelligence-acquires-novo-nordisk-s-parkinson-s-cell-therapy-program-with-fda-fast-track-status 2026-05-12T07:24:45+00:00 hourly 0.9 https://trial.medpath.com/news/myrtelle-reports-encouraging-clinical-data-for-myr-101-gene-therapy-in-canavan-disease-at-asgct-2026 2026-05-12T07:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/om1-s-ai-platform-enables-landmark-650000-patient-real-world-evidence-study-supporting-fda-approval-of-hologic-s-hpv-screening-assay 2026-05-12T07:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/harvard-university-expands-research-alliance-with-northpond-labs-to-accelerate-healthcare-innovation-translation 2026-05-12T07:19:05+00:00 hourly 0.9 https://trial.medpath.com/news/form-bio-launches-ai-powered-formmanufacturing-platform-to-address-cgt-manufacturing-bottlenecks 2026-05-12T07:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/heron-therapeutics-reports-mixed-q1-2026-results-with-strong-acute-care-growth-despite-overall-revenue-decline 2026-05-12T07:13:44+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-s-covid-monoclonal-antibody-shows-superior-tolerability-profile-compared-to-mrna-and-protein-vaccines 2026-05-12T07:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/curacle-and-maptics-license-bispecific-antibody-mt-103-to-memento-medicines-in-1-08-billion-deal-for-retinal-disease-treatment 2026-05-12T07:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/fusion-antibodies-advances-dr5-humanised-antibody-for-treatment-resistant-cancers-with-extended-grant-support 2026-05-12T07:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/reponex-pharmaceuticals-secures-european-patent-for-inflammatory-bowel-disease-treatment-targeting-4-7-billion-market 2026-05-12T07:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/bologna-s-cellply-raises-eur7-15-million-to-advance-single-cell-analysis-platform-for-cell-therapy-development 2026-05-12T07:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/basf-launches-new-fermentation-plant-for-biological-crop-protection-products-in-germany 2026-05-12T07:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-completes-fda-surveillance-inspection-remains-on-track-for-bla-resubmissions 2026-05-12T07:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/first-randomized-trial-of-rna-therapy-in-heart-failure-shows-promise-for-novel-treatment-approach 2026-05-12T07:00:21+00:00 hourly 0.9 https://trial.medpath.com/news/pentixapharm-submits-ind-to-fda-for-phase-3-panda-trial-of-first-in-class-cxcr4-targeted-cardiovascular-diagnostic 2026-05-12T06:56:09+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-unveils-ambitious-five-year-plan-to-become-global-top-five-oncology-company-by-2035 2026-05-12T06:53:59+00:00 hourly 0.9 https://trial.medpath.com/news/emvision-expands-pivotal-fda-trial-to-include-acute-ischaemia-detection-for-stroke-diagnosis-device 2026-05-12T06:51:27+00:00 hourly 0.9 https://trial.medpath.com/news/robotic-wheelchair-market-to-reach-usd-425-72-million-by-2035-driven-by-ai-navigation-and-brain-computer-interfaces 2026-05-12T06:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-digoxin-fails-to-meet-primary-endpoint-in-largest-heart-failure-trial-despite-hospitalization-benefits 2026-05-12T06:42:26+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-rna-therapy-cdr132l-fails-to-meet-primary-endpoint-in-heart-failure-trial 2026-05-12T06:42:15+00:00 hourly 0.9 https://trial.medpath.com/news/rwanda-s-sovereign-bet-on-science-akagera-medicines-advances-novel-tb-drug-akg-100-into-phase-i-trials 2026-05-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/unc-health-pursues-certificate-of-need-approval-for-new-hospitals-in-asheville-and-wilmington 2026-05-11T15:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/belapectin-shows-promise-in-preventing-esophageal-varices-in-mash-cirrhosis-patients 2026-05-11T12:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/bridge-to-life-s-vitasmart-hope-technology-shows-promise-for-expanding-liver-transplant-donor-pool 2026-05-11T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/us-pharmaceutical-excipients-market-to-reach-5-58-billion-by-2035-driven-by-biologics-and-advanced-formulations 2026-05-11T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/aldeyra-therapeutics-faces-securities-class-action-over-alleged-misrepresentation-of-reproxalap-trial-data-following-fda-rejection 2026-05-11T04:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-secures-procedural-victory-in-mrna-patent-dispute-against-pfizer-biontech-covid-19-vaccine 2026-05-10T08:40:21+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-drug-regulator-mandates-safety-reporting-from-market-launch-date-to-strengthen-patient-monitoring 2026-05-10T08:37:11+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-india-s-first-subcutaneous-immunotherapy-for-lung-cancer-reducing-treatment-time-to-seven-minutes 2026-05-10T08:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/ensoma-reports-first-clinical-safety-data-for-groundbreaking-in-vivo-hematopoietic-stem-cell-gene-therapy 2026-05-10T08:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-advances-pnkp-inhibitor-toward-clinical-trials-with-nucro-technics-bioanalytical-partnership 2026-05-10T08:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-first-veterinary-vaccine-using-self-amplifying-rna-technology-for-cat-protection 2026-05-10T07:58:31+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-s-inbrx-106-shows-44-response-rate-in-head-and-neck-cancer-trial-doubling-pembrolizumab-efficacy 2026-05-10T07:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/fudan-cup-002-trial-demonstrates-strong-efficacy-of-anti-pd-1-triple-combination-in-second-line-cancer-of-unknown-primary-treatment 2026-05-10T07:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-bet-inhibitor-nhwd-870-receives-breakthrough-therapy-designation-for-rare-nut-carcinoma 2026-05-10T07:46:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-dual-purpose-medication-for-canine-separation-anxiety-and-noise-aversion 2026-05-10T07:45:41+00:00 hourly 0.9 https://trial.medpath.com/news/francis-medical-receives-fda-clearance-for-vanquish-water-vapor-ablation-system-for-localized-prostate-cancer 2026-05-10T07:41:10+00:00 hourly 0.9 https://trial.medpath.com/news/hovione-and-idc-launch-commercial-intranasal-drug-delivery-platform-with-single-use-dry-powder-device 2026-05-10T07:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/analysts-maintain-strong-buy-consensus-on-cullinan-management-cgem-with-significant-upside-potential 2026-05-09T12:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/hongene-biotech-demonstrates-advanced-sirna-manufacturing-capabilities-through-siranbio-s-dual-target-hepatitis-b-program 2026-05-09T10:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/brain-aging-study-reveals-coordinated-cellular-remodeling-in-the-hippocampus-between-ages-50-and-75 2026-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/actio-biosciences-initiates-phase-1b-2-trial-of-abs-1230-for-rare-pediatric-epilepsy 2026-05-08T17:54:59+00:00 hourly 0.9 https://trial.medpath.com/news/vitamin-b12-s-role-in-mitochondrial-health-and-muscle-function-new-insights-into-healthy-aging 2026-05-08T17:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/gabather-initiates-phase-ii-totems-trial-for-gt-002-in-schizophrenia-spectrum-disorders 2026-05-08T17:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/modicus-prime-secures-8m-to-scale-ai-compliance-platform-for-pharmaceutical-industry 2026-05-08T10:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/yarmouk-university-secures-u-s-patent-for-solvent-free-dry-coating-technology-in-pharmaceutical-manufacturing 2026-05-08T10:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-advances-mrna-hantavirus-vaccine-development-as-deadly-cruise-ship-outbreak-highlights-urgent-medical-need 2026-05-08T10:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/mexico-amends-health-supplies-regulations-patent-term-compensation-and-data-exclusivity-now-in-effect 2026-05-08T10:01:29+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-receives-japan-approval-for-first-in-class-stem-cell-therapy-for-meniscal-injuries 2026-05-08T09:57:24+00:00 hourly 0.9 https://trial.medpath.com/news/chance-pharma-receives-nmpa-acceptance-for-novel-asthma-treatment-cxg87-following-positive-phase-iii-trial 2026-05-08T05:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/tocilizumab-shows-promise-as-first-potential-treatment-for-deadly-hantavirus-infections 2026-05-08T01:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/mainehealth-and-tufts-launch-expanded-chronic-lyme-study-to-uncover-causes-of-persistent-symptoms 2026-05-07T21:17:13+00:00 hourly 0.9 https://trial.medpath.com/news/smartcella-expands-extroducer-r-licensing-portfolio-with-heqet-and-oloker-partnerships-for-cardiac-regeneration-and-refractory-angina 2026-05-07T21:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/mainehealth-receives-2m-to-establish-maine-s-first-clinical-research-unit-at-biddeford-hospital 2026-05-07T21:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-receives-multiple-buy-ratings-despite-insider-selling-activity-following-strong-q1-2024-financial-performance 2026-05-07T20:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/andes-hantavirus-outbreak-on-cruise-ship-who-confirms-human-to-human-transmission-three-dead 2026-05-07T17:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/parcelbio-emerges-from-stealth-with-13m-to-advance-durable-mrna-platform-for-chronic-diseases 2026-05-07T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-develops-novel-screening-platform-for-cyclic-peptides-targeting-challenging-membrane-proteins 2026-05-07T17:18:20+00:00 hourly 0.9 https://trial.medpath.com/news/sk-pharmteco-partners-with-nih-and-axle-informatics-to-advance-rare-disease-gene-therapies 2026-05-07T17:14:02+00:00 hourly 0.9 https://trial.medpath.com/news/blackstone-invests-250-million-in-anagram-therapeutics-to-advance-novel-enzyme-therapy-for-pancreatic-insufficiency 2026-05-07T17:13:48+00:00 hourly 0.9 https://trial.medpath.com/news/milliporesigma-secures-exclusive-five-year-testing-agreement-for-genetix-biotherapeutics-fda-approved-gene-therapies 2026-05-07T17:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/altasciences-and-certara-form-strategic-partnership-to-accelerate-early-phase-drug-development 2026-05-07T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/scarlet-therapeutics-achieves-breakthrough-with-lab-grown-universal-red-blood-cells-matching-donor-cell-survival 2026-05-07T17:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/neuland-laboratories-partners-with-lir-life-sciences-to-develop-transdermal-glp-1-obesity-treatment 2026-05-07T09:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-investigational-pet-tracer-i-124-evuzamitide-meets-primary-endpoints-in-phase-iii-cardiac-amyloidosis-study 2026-05-07T09:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-expands-strategic-alliance-with-cancer-research-uk-to-accelerate-novel-cancer-therapy-development 2026-05-07T09:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/nona-biosciences-appoints-dr-josh-xiao-as-chief-scientific-officer-to-advance-ai-driven-drug-discovery-platform 2026-05-07T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/largest-blood-protein-genetics-study-reveals-new-precision-medicine-opportunities-including-tyk2-inhibitor-repurposing-for-rheumatoid-arthritis 2026-05-07T05:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-reports-strong-q1-performance-with-brukinsa-leading-growth-and-pipeline-advances 2026-05-07T01:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gene-therapy-and-dna-vaccine-approaches-show-promise-for-functional-hiv-cure 2026-05-07T01:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-secures-german-reimbursement-for-crispr-gene-therapy-casgevy-in-sickle-cell-disease-and-beta-thalassemia 2026-05-07T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/image-analysis-group-and-heartcor-solutions-form-strategic-partnership-to-streamline-clinical-trial-cardiac-safety-and-imaging-services 2026-05-07T01:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/lqr-house-partners-with-hangzhou-gsy-biotechnology-to-develop-functional-wellness-beverages-using-proprietary-fermentation-technology 2026-05-07T01:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/kanvas-biosciences-raises-48m-series-a-to-advance-microbiome-based-cancer-immunotherapy 2026-05-07T01:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-enhanced-dosing-options-for-crysvita-in-adults-with-x-linked-hypophosphatemia 2026-05-06T21:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/first-blood-test-to-map-the-tumor-microenvironment-unveiled-by-stanford-and-mayo-clinic-researchers 2026-05-06T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-beats-q1-revenue-estimates-as-licensing-strategy-drives-growth-amid-covid-vaccine-demand-decline 2026-05-06T21:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-withdraws-diabetes-drug-teplizumab-from-fda-fast-track-review-amid-safety-concerns 2026-05-06T21:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-invests-additional-4-5b-in-indiana-manufacturing-opens-first-genetic-medicine-facility 2026-05-06T17:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/lobe-sciences-advances-l-130-for-chronic-cluster-headache-and-s-100-for-sickle-cell-disease-targets-late-2026-ind-filing 2026-05-06T17:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/ltz-therapeutics-secures-38-million-to-advance-universal-myeloid-cell-engager-immunotherapy-platform 2026-05-06T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/abli-therapeutics-strengthens-board-with-neurodegeneration-expert-dr-rachelle-doody-ahead-of-phase-3-trials 2026-05-06T17:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/upc-central-division-revokes-chinese-military-medical-institute-s-remdesivir-patent-in-landmark-inventive-step-ruling 2026-05-06T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/magnesium-channel-blocker-cpacc-reverses-obesity-and-fatty-liver-disease-in-mice-on-western-diet 2026-05-06T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/cdt-advances-myeloperoxidase-inhibitor-azd5904-into-global-patent-phase-for-male-infertility-treatment 2026-05-06T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/scienture-secures-third-patent-for-arbli-losartan-oral-suspension-extending-market-exclusivity-through-2041 2026-05-06T17:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/pathos-ai-acquires-majority-stake-in-deuteroncology-to-advance-ai-identified-met-inhibitor-do-2 2026-05-06T17:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/infant-bacterial-therapeutics-advances-toward-fda-approval-for-ibp-9414-in-premature-infants 2026-05-06T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/russia-s-biocad-initiates-phase-iii-trial-of-kadcyla-biosimilar-bcd-237-for-her2-positive-breast-cancer 2026-05-06T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/testosterone-suppresses-glioblastoma-growth-in-males-nih-funded-study-finds 2026-05-06T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-one-day-inspection-pilot-using-ai-to-target-low-risk-manufacturing-facilities 2026-05-06T17:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/ontario-lowers-colorectal-cancer-screening-age-to-45-joining-prince-edward-island-in-landmark-policy-shift 2026-05-06T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-achieves-commercial-ready-manufacturing-for-cordstromtm-platform-paving-way-for-global-regulatory-filings-in-rdeb 2026-05-06T13:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-acquires-perfuse-therapeutics-for-2-45-billion-to-advance-novel-glaucoma-and-diabetic-retinopathy-treatment 2026-05-06T13:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/tissue-dynamics-and-galmed-partner-to-develop-novel-cardiac-fibrosis-platform-using-human-organoids-and-ai 2026-05-06T13:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-biosciences-and-nextcell-launch-commercial-msc-research-platform-to-address-cell-therapy-development-challenges 2026-05-06T13:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/908-devices-acquires-nirlab-ag-to-strengthen-narcotics-detection-capabilities 2026-05-06T11:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/immutrin-appoints-cardiovascular-expert-dr-robert-blaustein-as-cmo-to-advance-amyloidosis-therapy 2026-05-06T09:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/andes-hantavirus-outbreak-on-antarctic-cruise-ship-global-public-health-response-and-clinical-updates 2026-05-06T08:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/mingmed-biotechnology-s-qa102-shows-promise-in-phase-ii-trial-for-intermediate-dry-amd 2026-05-06T05:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/zyus-life-sciences-secures-second-u-s-patent-for-cannabichromene-based-pain-management-therapy 2026-05-06T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-blocks-publication-of-studies-finding-covid-19-and-shingles-vaccines-safe 2026-05-06T01:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-first-fruit-flavored-e-cigarettes-for-adult-smokers-in-policy-shift 2026-05-06T01:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/mammaprint-genomic-profiling-predicts-anthracycline-benefit-in-hr-her2-early-breast-cancer-guiding-nccn-guideline-update 2026-05-05T22:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/vectorbuilder-secures-european-patent-for-minivectm-plasmid-system-advancing-gene-therapy-manufacturing 2026-05-05T21:17:41+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-ottava-robotic-system-meets-primary-endpoints-in-gastric-bypass-surgery-trial 2026-05-05T21:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/cvs-health-drops-j-j-s-stelara-from-main-formularies-in-favor-of-lower-cost-biosimilars 2026-05-05T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/tris-pharma-launches-adneuris-therapeutics-to-advance-first-in-class-dual-nmr-agonist-cebranopadol-for-moderate-to-severe-acute-pain 2026-05-05T17:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/tegoprazan-demonstrates-superior-healing-and-maintenance-in-phase-3-erosive-esophagitis-trial 2026-05-05T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/dupixent-demonstrates-disease-modifying-effects-in-eosinophilic-esophagitis-phase-4-trial 2026-05-05T17:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/myphenome-genetic-test-predicts-weight-loss-outcomes-across-glp-1-and-surgical-obesity-treatments-mayo-clinic-studies-show 2026-05-05T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/mimivax-and-roswell-park-launch-phase-2-trial-of-survaxm-cancer-vaccine-for-metastatic-neuroendocrine-tumors 2026-05-05T17:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/non-viral-gene-therapies-gain-momentum-as-safety-concerns-drive-industry-shift-from-viral-vectors 2026-05-05T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/viralgen-partners-with-elaaj-bio-to-advance-gene-therapy-for-rare-pediatric-disorder-cdkl5-deficiency 2026-05-05T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-to-close-german-manufacturing-site-in-wehr-by-2028-affecting-220-jobs 2026-05-05T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/transcelerate-and-fda-collaborate-on-streamlined-safety-data-collection-to-advance-pragmatic-clinical-trials 2026-05-05T17:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/anteris-technologies-initiates-u-s-enrollment-in-paradigm-trial-for-novel-biomimetic-heart-valve 2026-05-05T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/tissium-secures-up-to-eur60m-financing-to-accelerate-commercial-rollout-of-sutureless-nerve-repair-platform 2026-05-05T13:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-cs-1103-for-fentanyl-overdose-reversal 2026-05-05T13:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/cytospire-raises-83m-series-a-to-advance-novel-gamma-delta-t-cell-engagers-for-cancer-treatment 2026-05-05T09:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-breakthrough-gene-therapy-to-restore-hearing-in-children-born-deaf 2026-05-05T09:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-repurchases-90-million-in-royalty-certificates-streamlining-capital-structure-ahead-of-obefazimod-commercialization 2026-05-05T09:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-biotech-sector-achieves-record-revenue-and-38-private-funding-surge-in-2025 2026-05-05T09:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/xbrane-and-intas-revise-financing-terms-for-opdivo-biosimilar-xdivane-development 2026-05-05T09:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/tlx250-px-shows-promise-for-diagnosing-multiple-kidney-cancer-types-beyond-clear-cell-renal-cell-carcinoma 2026-05-05T01:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/recludix-s-oral-stat6-inhibitor-rex-8756-shows-efficacy-comparable-to-monoclonal-antibodies-in-atopic-dermatitis-model 2026-05-04T21:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/palopegteriparatide-shows-sustained-3-year-benefits-in-hypoparathyroidism-treatment 2026-05-04T21:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/proton-beam-therapy-shows-promise-as-noninvasive-treatment-for-refractory-ventricular-tachycardia 2026-05-04T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/probio-launches-viral-vector-packaging-test-to-accelerate-cell-and-gene-therapy-development 2026-05-04T21:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/sgs-acquires-keystone-bioanalytical-to-expand-north-american-drug-development-testing-capabilities 2026-05-04T21:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/retroviral-vectors-are-back-can-manufacturing-keep-pace-with-the-cgt-revolution 2026-05-04T21:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/first-ever-sperm-production-achieved-after-re-transplanting-childhood-frozen-testicular-tissue 2026-05-04T21:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/ctibiotech-launches-us-operations-with-27-million-investment-to-advance-3d-bioprinting-for-drug-development 2026-05-04T21:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/general-proximity-secures-investment-from-freemind-and-daewoong-for-next-generation-induced-proximity-platform 2026-05-04T17:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-targets-30-cancer-burden-reduction-by-2030-explores-car-t-cell-therapy-adoption 2026-05-04T17:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/latus-bio-secures-97m-series-a-to-advance-gene-therapy-pipeline-for-neurodegenerative-diseases 2026-05-04T17:29:11+00:00 hourly 0.9 https://trial.medpath.com/news/kubota-vision-partners-with-laboratoires-kol-to-provide-emixustat-for-stargardt-disease-under-compassionate-use-in-france 2026-05-04T17:29:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-asceniv-label-to-include-pediatric-patients-as-young-as-two-years-for-primary-immunodeficiency-treatment 2026-05-04T17:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/windward-bio-secures-165m-to-advance-ultra-long-acting-immunology-therapies-for-asthma-and-copd 2026-05-04T17:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/caplyta-shows-superior-efficacy-among-adjunctive-depression-treatments-in-first-network-meta-analysis 2026-05-04T17:27:03+00:00 hourly 0.9 https://trial.medpath.com/news/decentralized-clinical-trials-fda-and-ema-guidance-highlights-strategic-value-of-hybrid-designs-over-fully-virtual-models 2026-05-04T17:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/istios-health-partners-with-care-id-to-bridge-clinical-trial-access-gap-in-infectious-disease-research 2026-05-04T13:05:36+00:00 hourly 0.9